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ABSTRACT

Lung cancer is the leading cause of cancer-related mortality in the US. Emerging
evidence has shown that host genetic factors can interact with environmental exposures to
influence patient susceptibility to the diseases as well as clinical outcomes, such as survival
and recurrence. We aimed to identify genetic prognostic markers for non-small cell lung
cancer (NSCLC), a major (85%) subtype of lung cancer, and also in other subgroups. With
the fast evolution of genotyping technology, genetic association studies have went through
candidate gene approach, to pathway-based approach, to the genome wide association study
(GWAS). Even in the era of GWAS, pathway-based approach has its own advantages on
studying cancer clinical outcomes: it is cost-effective, requiring a smaller sample size than
GWAS easier to identify a validation population and explore gene-gene interactions. In the
current study, we adopted pathway-based approach focusing on two critical pathways miRNA and inflammation pathways. MicroRNAs (miRNA) post-transcriptionally regulate
around 30% of human genes. Polymorphisms within miRNA processing pathways and
binding sites may influence patients’ prognosis through altered gene regulation.
Inflammation plays an important role in cancer initiation and progression, and also has
shown to impact patients’ clinical outcomes.
We first evaluated 240 single nucleotide polymorphisms (SNPs) in miRNA biogenesis
genes and predicted binding sites in NSCLC patients to determine associations with clinical
outcomes in early-stage (stage I and II) and late-stage (stage III and IV) lung cancer patients,
respectively. First, in 535 early-stage patients, after correcting multiple comparisons,
FZD4:rs713065 (hazard ratio [HR]:0.46, 95% confidence interval [CI]:0.32-0.65) showed a
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significant inverse association with survival in early stage surgery-only patients.
SP1:rs17695156 (HR:2.22, 95% CI:1.44-3.41) and DROSHA:rs6886834 (HR:6.38, 95%
CI:2.49-16.31) conferred increased risk of progression in the all patients and surgery-only
populations, respectively. FAS:rs2234978 was significantly associated with improved
survival in all patients (HR:0.59, 95% CI:0.44-0.77) and in the surgery plus chemotherapy
populations (HR:0.19, 95% CI:0.07-0.46).. Functional genomics analysis demonstrated that
this variant creates a miR-651 binding site resulting in altered miRNA regulation of FAS,
providing biological plausibility for the observed association. We then analyzed these
associations in 598 late-stage patients. After multiple comparison corrections, no SNPs
remained significant in the late stage group, while the top SNP NAT1:rs15561 (HR=1.98,
96%CI=1.32-2.94) conferred a significantly increased risk of death in the chemotherapy
subgroup.
To test the hypothesis that genetic variants in the inflammation-related pathways may be
associated with survival in NSCLC patients, we first conducted a three-stage study. In the
discovery phase, we investigated a comprehensive panel of 11,930 inflammation-related
SNPs in three independent lung cancer populations. A missense SNP (rs2071554) in HLADOB was significantly associated with poor survival in the discovery population (HR: 1.46,
95% CI: 1.02-2.09), internal validation population (HR: 1.51, 95% CI: 1.02-2.25), and
external validation (HR: 1.52, 95% CI: 1.01-2.29) population. Rs2900420 in KLRK1 was
significantly associated with a reduced risk for death in the discovery (HR: 0.76, 95% CI:
0.60-0.96) and internal validation (HR: 0.77, 95% CI: 0.61-0.99) populations, and the
association reached borderline significance in the external validation population (HR: 0.80,
95% CI: 0.63-1.02). We also evaluated these inflammation-related SNPs in NSCLC patients
vi

in never smokers. Lung cancer in never smokers has been increasingly recognized as distinct
disease from that in ever-smokers. A two-stage study was performed using a discovery
population from MD Anderson (411 patients) and a validation population from Mayo Clinic
(311 patients). Three SNPs (IL17RA:rs879576, BMP8A:rs698141, and STK:rs290229) that
were significantly associated with survival were validated (p<0.05), and two more SNPs
(CD74:rs1056400 and CD38:rs10805347) were borderline significant (p=0.08) in the Mayo
Clinic population. In the combined analysis, IL17RA:rs879576 resulted in a 40% reduction
in the risk for death (p=4.1 × 10-5 [p=0.61, heterogeneity test]). We also validated a survival
tree created in MD Anderson population in the Mayo Clinic population.
In conclusion, our results provided strong evidence that genetic variations in specific
pathways that examined (miRNA and inflammation pathways) influenced clinical
outcomes in NSCLC patients, and with further functional studies, the novel loci have
potential to be translated into clinical use.
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Chapter 1: General Introduction
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1.1

Epidemiology

1.1.1

Incidence and mortality

Lung cancer incidence increases dramatically since last century, and it is now the second
most common cancer in both sexes and the leading causes of cancer death worldwide (1).
Although the incidence rate has reduced in men (1.9% per year) and started to decline in
women (0.3% per year), it is estimated that 226,160 new lung cancer cases will be
diagnosed in 2012, accounting for 14% of all new cancer diagnoses (2, 3).
Around 95% of all lung cancer cases are classified into two major histological types –
non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) and. NSCLCs
develop from epithelial cells, while SCLCs originate from neuroendocrine-cells. Around 85%
of lung cancer cases are NSCLCs. NSCLCs can be classified into several subtypes
according to physical and chemical characteristics of tumor cells. Adenocarcinoma is slowgrowing tumors that account for around 40% of all NSCLCs. Patients are usually diagnosed
before the tumors reach 4 cm in diameter and have a better prognosis compared to other
subtypes (4, 5). Around 25% to 30% of NSCLC cases are squamous cell carcinoma, usually
observed with a tumor larger than 4cm (4). 10-15% of NSCLC patients have large cell
carcinoma, where the tumors are often poorly differentiated, grow rapidly, and metastasize
early (6).
The highest lung cancer incidence in male observed in the central and Eastern Europe,
while African and Asian men have the lowest incident rate. In female, the highest incidence
was found in North America, and in some part of Europe. Women in Spain is the least likely
to develop lung cancer, where the percentage of women smoker just begin to increase (7).
Within the same geographic location, lung cancer incidences are usually different between
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ethnic groups, for example, in the US, black male has the highest incident rate of lung
cancer, which is 40% higher in black men compared to white men (Cancer Facts & Figures
2012).
Despite of the declining mortality rate in both men and women, lung cancer is still the
leading cause of cancer-related mortality in the US. Emerging evidence shows that early
stage lung cancer patients received surgery have good survival; however, most of lung
cancer patients diagnosed with un-resectable tumor, thus the overall mortality for lung
cancer remain very high. It is expected that over a quarter of all cancer-related deaths will be
attributed to lung cancer this year, more than colon, breast and prostate cancer combined (2).

1.1.2

Risk Factors

1.1.2.1 Tobacco smoking
It is estimated that tobacco smoking is related to around 80% of all cancer deaths. Ever
since 1950s, tobacco smoking has been recognized as the leading risk factor for lung cancer.
Smokers have at least ten-time higher risk of developing lung cancer compared to those who
never smoked, and the excess risk was equally observed in both male and female (8).
Factors of smoking influence lung cancer risk include duration of smoking, smoking
intensity (i.e. number of cigarettes per day)age of initiation, inhaling habit, types of tobacco
products and time since quitting. Data has shown that more than 90% of lung cancer cases
are caused by tobacco smoking (9, 10).
For current smokers, lung cancer risk is proportional to the pack-year of smoking. The
cumulative risk for continuous smokers is 19%, compared to 1% in never smokers at age of
75 (11). Former smokers have lower risk of lung cancer, however, excess risk of lung
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cancer was still observed compared to never smokers. Other type of smoking, such as pipes,
or cigars also showed related to increased lung cancer risk.
Lung cancer in never smokers - Although smoking is the predominant risk factors for
lung cancer, lung cancer develops in 15% of male and 53% of female never-smokers (12,
13). Over the past few decades, the proportion of never-smokers with lung cancer has
increased strikingly (13). Lung cancer in never smokers has emerged as a major public
health problem in studies tracking smoking and smoking cessation rate. Previous studies
have reported differing tumor etiology and clinicopathological presentation according to
smoking status in lung cancer patients with never-smokers as being more likely to be
women, having adenocarcinomas, and having less-differentiated tumors (12-15). Genetic
and epigenetic alterations also differ with fewer changes overall. Tumors from neversmokers also have a unique and predominant profile compared to those from smokers, such
as chromosomal gains at 16p, promoter hypermethylation of hMLH1 and hMSH2, and
distinct mutations of major oncogenes and tumor suppressor genes. For example, compared
to smokers, never smokers have fewer mutations in K-ras and tp53 genes, while with a
higher rate of mutation in EGFR, results in better response rate of EGFR tyrosine kinase
inhibitors in never smokers (12-14). These findings suggest different paths of
carcinogenesis in ever- and never-smokers with lung cancer.

1.1.2.2 Environmental and occupational exposure
In the US, around 40% of non-smokers are currently exposed to environmental second
hand smoke (16). Second-hand smoking leads to up to 30% increased risk for those who do
not smoke, which is estimated to contribute to three thousands lung cancer deaths each year
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(17). Evidence shows that second-hand smoking is comparable to smoking in the excess risk
of lung cancer.
Radon is another environmental risk factor for lung cancer, which commonly released
from construction material concentrated in buildings, and is hard to be detected without
specialized equipment. Based on the data from U.S. Environmental Protection Agency,
radon is responsible for over 20,000 lung cancer cases each year, which makes it a major
risk factor for lung cancer, especially in never smokers.
Occupational asbestos exposure is another important risk factor for lung cancer. People
who worked in an environment with asbestos fibers have much higher risk to develop and
die from lung cancer. Moreover, joint effect was observed for asbestos exposure with
tobacco smoking.
Other environmental risk factors include air pollutions, diesel exhaust, and arsenic.
Certain forms of silica and chromium also show associations with lung cancer.

1.1.2.3 Other risk factors
People with family or personal history of cancer are at higher risk of developing lung
cancer. First-degree relatives of lung cancer patients have higher risk and/or early onset of
the disease. Evidence shows that persons who received radiation therapy to the chest, or to
other cancers, have an increased risk of developing lung cancer.
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1.2

Clinical Aspects

1.2.1

General overview

The most common lung cancer symptoms include: a persistent cough, chest pain,
hoarseness, shortness of breath, wheezing, infections, bone pain, neurologic changes, and
jaundice. Lung cancer patients are usually diagnosed with advanced stage diseases, due to
the late presentation of symptoms or lack of symptoms (18-22).
TNM staging system, which maintained by the American Joint Committee on Cancer
(AJCC) and the International Union Against Cancer (UICC), is the widely accepted standard
for NSCLC staging. Clinical stage is defined by physical exam, biopsies, imaging tests prior
to treatment. Patients who undergo surgical resection may also have pathologic stage based
on histological tests of resected tumor, which can provide more accurate information about
the extent of disease(23).
The treatment options for NSCLC includes surgery, radiation therapy, chemotherapy,
target therapy and other local treatments, and treatments are usually used in combinations
(24-26). Even with advances in treatment, the overall prognosis is still poor for NSCLC,
with an overall 5-year survival rate (percentage of patients survival at least 5 years after
diagnosis) of around 16% (1). In general, surgery is considered the most potentially curative
treatment for early stage NSCLC and offers the best prognosis. Evidence shows that
complete resection of localized tumor and associated lymph node largely benefit patients
prognosis, and a post-operative chemotherapy could add significant benefit to patients’
survival (27).
The clinicopathologic factors most often associated with prognosis include stage of
cancer (tumor size and spread of disease), type of cancer (non-squamous histology),
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presence of pulmonary symptoms, lymph nodes metastases, vascular invasion. Effort has
been devoted to developing prediction modalities for patient prognosis based on these
clinicopathologic factors; however, variations still exist within patients with same above
mentioned characteristics (28-32).

1.2.2

Prognosis and treatment by stage

The TNM stage at diagnosis is the primary parameter used to estimate patients’ prognosis
and treatments. Early stage patients have the most promising 5-year survival rate of 30-49%,
while survival for late stage patients is as low as 1% for stage IV patients (the Surveillance,
Epidemiology and End Results [SEER] databases). A validation-study series using more
than 31,000 lung cancer cases has provided the most extensive data of survival for each
stage of patients (Figure 1), and a 59 months survival disparity was observed between stage
IA and stage IV patients (33). Because the large difference in prognosis between patients
with resectable and advanced diseases (34), the prognostic factors are commonly identified
separately (Tables 1 and 2).
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Figure 1 Overall survival, median survival time and five-year survival by TNM stage
(A) clinical stage and (B) pathologic stage. (33) Reprinted by permission from J
Thorac Oncol, copyright (2007)
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About 30% of NSCLCs are diagnosed with early stage disease (stage I and II), which is
considered as a localized disease and expected to have a generally good survival. Stage I
patients are defined as those having a tumor limited to the lung without any invasion to the
parietal pleura or main bronchi (35). Stage II NSCLC tumors are still in lung with or without
invasion into local lymph nodes, and have not spread to distant sites. Surgical resection is
the principle treatment for early stage NSCLCs. To obtain better outcome, chemotherapy
(neoadjuvant/ adjuvant) and radiation therapy were performed to facilitate surgical resection
and prevent recurrence when necessary (28, 36, 37). However, it is estimated that 20-25%
of stage I or II patients will eventually develop recurrent or metastatic disease. Prevention of
recurrence is the major concern for this group of patients (28).
A majority of NSCLC cases are diagnosed with late (stage III or IV) stage diseases,
which are usually incurable. Typically, these patients present with metastatic disease, and
only a few stage IIIA patients are eligible for surgery. Overall, late stage patients have a
dismal 5-year survival rate of 5% (38). Standard treatment for these patients is platinumbased chemotherapy, which is reported to moderately prolong patients’ survival (39, 40).
Radiation therapy is usually performed in combination with chemotherapy either
concurrently or sequentially. However, the response rate to chemotherapy is only 30% with
a duration limited to 4-6 months. Furthermore, patients are at high risk for developing severe
toxic effects (41). Therefore, patients with late stage disease are usually administered
palliative treatments to reduce symptoms and improve quality of life (42, 43). As curative
options are limited for these patients, a subset of this group may benefit from targeted
therapies and may be candidates for clinical trials.
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Table 1: Prognostic Factors in Patients With Surgically Resected NSCLC
Prognostic Factors
Essential factors

Additional factors

New or promising
factors

Tumor-Related Factors
Stage
Hypercalcemia54

“N” factor

Anatomic
“T” factor
Nodal level
Intrapulmonary metastasis
Histologic
Grade
Vessel invasion
Histologic
Cells in mitosis
Lymphoid infiltration
Clinical chemistry
Blood group Ag
NSE
CA-125
TPA
Proliferation markers
DNA ploidy and/or % S-phase
PCNA
Thymidine labeling
Cellular adhesion markers
CD44
Other molecular biological markers
kRAS, RB gene, bcl-2, c-jun, MRP1, EGFr (c-erbB-1), HGF, TPA,
Cyclin D-1, P53, P21, c-fos, CYFRA21-1, KAI-1, c-erbB-2, VEGF, sIL2R, Cathepsin B

Tumor size
Pleural cytology

Host-Related
Factors
Weight loss
Performance
status
Sex
Age

Cell type

Angiogenesis

Coagulation
factors
Proteinuria
CEA

Smoking habit
Quality of life
Marital status
Depressed mood
CYPIA-1

Ki67
AgNOR

Plankoglobin

* NSE = neuron-specific enolase; CEA = carcinoembryonic antigen; AgNOR =
argyrophilic nucleolar organizer region; PCNA = proliferating cell nuclear antigen; RB
= retinoblastoma; CYFRA-21 = serum assay for detection of cytokeratin 19 fragment;
MRP = motility-related protein; kRAS = ras oncogene or protein; EGFr = epidermal
growth factor receptor; HGF = hepatocyte growth factor; VEGF = vascular endothelial
growth factor. Reprinted by permission from American College of Chest Physicians. (34)
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Table 2: Prognostic Factors in Patients With Advanced NSCLC
Prognostic Factors
Essential factors

Additional factors

New or promising
factors

Tumor-Related Factors
Stage (III vs IV)
Hypercalcemia
SVCO
Anatomic
“T” factor
”N” factor
Clinical stage IIIA vs IIIB
Number of sites involved
Pleural effusion
Liver metastases
Clinical chemistry/hematology
Hemoglobin
LDH
Albumin
Clinical chemistry/hematology
Coagulation factors
Proteinuria
Proliferation markers
DNA ploidy and/or % S-phase
Ki-67
Other molecular biologic markers
Replication errors 2p/3p
K ras
P53
c-erbB-1
TPA
NSE
Other radiology
Thalium-201 uptake

Host-Related Factors
Weight loss
Performance status
Sex
Symptoms
Age

Quality of life
Marital status
Depressed mood
CYPIA1

* SVCO = superior vena caval obstruction; NSE = neuron-specific enolase.
Reprinted by permission from American College of Chest Physicians. (34)
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1.3

Genetics of lung cancer

1.3.1

Somatic alterations

Numerous molecular genetic abnormalities have been identified in lung cancer, such as
chromosomal aberrations, alterations in major tumor suppressor gene (TSG) or oncogenes,
many of the alterations are of great clinical importance (44, 45).
The most common identified mutation of lung cancers were in KRAS and the epidermal
growth factor receptor (EGFR) tyrosine kinase gene. KRAS mutations, common form of RAS
mutations, have been identified in lung tumors for two decades. Studies have shown that
around 23% of all lung cancer cases carrying KRAS mutations, mostly in codons 12/13.
Considerable efforts have been devoted to evaluate the predicting value of KRAS mutation
on cancer drug response, which provided some evidence that KRAS might predict a poor
response to adjuvant chemotherapy and kinase inhibitors (46-48). EGFR mutations are
found in 15%-30% of NSCLC tumors (49). Although just recently identified in NSCLCs,
EGFR mutations have attracted considerable attentions from clinics. EGFR mutations,
especially in kinase domain, have been used as predictors for treatment response of EGFR
kinase inhibitors, such as gefitinib. Other than KRAS and EGFR, other somatic mutations,
such as BRAF, ERBB2 and TP53, are also frequently identified in lung tumors.
Other genetic alterations, such as chromosomal alterations, somatic copy-number
alteration, and loss-of heterogeneity (LOH), are also frequently found in lung cancer (50-52).
For example, the loss of chromosome 3p has been identified in nearly half of non-small cell
tumors (53), and LOH was observed in 90% of lung squamous cell carcinoma and in 67% of
lung adenocarcinoma (52).
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Somatic alterations have been investigated for their associations with prognosis (44, 45).
For example, down-regulation of 3p genes (RASSF1A, FHIT, β-catenin) were found related
with a poorer survival in NSCLC (54-56). In addition, many studies have found the role of
several major oncogenes and TSGs in NSCLC prognosis. NSCLC tumors harboring KRAS
mutations are smaller and poorly differentiated, patients have a higher mortality rate (57).In
a study of advanced stage patients, it was found that compared to patients with KRAS
mutated tumor, patients carrying BRAF mutations experienced a better prognosis (58, 59).
Some other genes, such as growth factors (60), apoptosis genes (61), DNA repair gene (6265), telomerase activity (66), inflammatory factors (67-70), plasminogen activator (71, 72),
and matrix metalloproteinases (73) have also been described for their prognostic value.

1.3.2

Genetic susceptibility

Evidence of familial aggregation of lung cancer suggested a role of genetic components
to lung cancer (74-77) . For example, in a family-based study, a 2.4-fold increased risk of
lung cancer was observed for the individuals whose relatives had developed lung cancer, the
effect remained significant even after controlling for other risk factors (75). And in a recent
large scale family linkage study of lung cancer, it was found that among 26,000 lung cancer
patients screened in the study, 13.7% had at least one first-degree relative also developed
lung cancer. The excess risk of lung cancer patients’ relatives suggested the potential
heritability of lung cancer. Association studies also provided supporting evidence of genetic
component in the initiation and progression of lung cancer. Knowledge of lung cancer
susceptibility genetic loci is the key for the understanding of the underlying mechanism of
disease initiations and progressions. In general, lung cancer susceptibility genes were
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categorized into high or moderate/ low risk (or penetrance) genes, for which family-based
linkage analysis or genetic association studies were performed.

1.3.2.1 Linkage analysis
The traditional strategy to identify high penetrance gene is the family-based linkage
analysis followed by positional cloning. Family-based analysis can avoid potential bias
caused by environmental factors, and has successfully mapped lots of genes associated with
monogenic disorder including common cancers(78). High risk gene has a great impact on
cancer risk for people carrying the variant allele, however, the frequency of variant allele of
high-risk gene is very low in population, and thus the population attributable risk is low.
Most of the high-risk genes are tumor suppressor genes (TSGs) discovered in the study of
cancer syndromes, and show an autosomal dominant inherited fashion (Mendelian pattern)
(79).
There are several gene mutation identified as potential high risk for lung cancer. For
example, TP53 mutations identified in family members with Li-Fraumeni syndrome were
significantly associated with higher lung cancer risk and earlier age at onset. A family
linkage study mapped a higher risk region to chromosome 6q23-25 (80), fine mapping of
sequential studies further narrow it to RGS17gene (81, 82).

1.3.2.2 Genetic association studies
Despite the great impact of high-penetrance genes on cancer development of individuals
carrying mutated genes, it only accounts for 10% of cancers, and the remaining 90% of
cancer were considered developing in a polygenic fashion with a complex interaction of
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both environmental factors and multiple small and subtle genetic changes. Although only
small proportion of people carrying low penetrance genes will develop cancer, and the effect
of these low-penetrance genes usually cannot be distinguished clearly from environmental
effect, the high prevalence of these low-penetrance genes in general population makes their
identification of great impact in public health. Traditional family-based linkage analysis
failed to identify this type of genes due to population heterogeneity and environmental
confounders.(79) During the past decades, population-based association study has proved its
value in discovering low/moderate penetrance loci. Based on “common disease common
variant” hypothesis, association study identifies cancer susceptibility loci by comparing the
frequency of the genetic variants between cancer patients and healthy controls. Numerous
studies, particularly recent genome-wide association studies (GWAS), have unequivocally
identified many low penetrance genetic loci for a variety of cancers(83).
Single nucleotide polymorphisms (SNP) are most commonly investigated form of genetic
variations in cancer association studies. Evidence shows that SNPs would affect host gene
either in terms of gene expression or protein activities, and have impact on lung cancer
susceptibility and outcomes (84-86). Association studies can be either family- or populationbased. By comparing the allele frequency of candidate loci between cases and healthy
controls, population-based association studies are more widely used in cancer gene
identification than family-based association study, in which elderly relatives of cancer
patients are hard to recruit. Population-based association study has gone through a fast
evolvement in the past decades, from candidate gene approach to pathway-based approach
to genome-wide association approach (87, 88), and have been widely adopted in the
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identification of low penetrate common alleles responsible for cancer susceptibility as well
as patients’ prognostic markers.

Candidate gene and pathway-based approach - Candidate gene approach is the earliest
approach used to identify cancer susceptibility genes. This hypothesis driven approach is
largely depending on a priori knowledge of SNPs and gene function. Most of the genes
selected as candidate are genes encoding proteins within major known functional pathways
and the SNPs are functional SNPs. Since the number of SNPs is limited, the genotyping cost
is relatively low, and the sample size requirement is small. Pathway-based approach is an
extension for candidate gene approach. Instead of analyzing a single gene or single variant,
this approach focuses on gene variants of a whole biological or functional pathway.
Pathway-based approach increases the coverage of analyzed region, but is still hypothesisdriven and based on existing knowledge. Because of the increasing number of variant
genotyped, the cost of genotyping increases and chance of false discovery also increases. (86)
With its own strength of being based on prior knowledge of disease biology, candidate
gene and pathway based approaches have been widely adopted to identify genetic predictors
for lung cancer susceptibility loci (86). DNA repair pathway gene polymorphisms are most
commonly identified to be associated with susceptibility of lung cancer (89-92). For
example, polymorphisms in XRCC1 have repeatedly been identified to associate with lung
cancer susceptibility (93-96). In a meta-analysis of 28 published epidemiological studies on
nucleotide excision repair pathway gene, it was found that ERCC2751Gln/Gln and
XPA 23G/G genotype were significantly associated with altered lung cancer risk (97).
Besides the above mentioned studies, numerous studies on other pathways, such as cell
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cycle (98-100), growth signaling (101-103), and apoptosis (85) pathways, have been
identified as lung cancer susceptibility loci. Over past a few decades, studies have started to
used candidate gene/ pathway-based approaches to investigate lung cancer outcomes, such
as polymorphisms in DNA repair pathway (104-107), AKT/mTOR pathway (108-110),
miRNA pathway (111-113), have showed evidence to related to survival in lung cancer
patients.

Genome-wide association studies (GWAS) - not depending on any current knowledge,
GWAS is a discovery-driven approach, providing a thorough screening of whole
genome(114). Due to the large number of association tested, the requirement for statistical
significance is very stringent (P-value<10-8) and a multi-stage study design is usually
performed to control for false discovery through successive validation steps (115).
Recent reports have clearly demonstrated the power of GWAS in identifying novel
genetic loci of common diseases (83). Till date, fifteen GWAS studies have been reported
on lung cancer (116-131). Compared to the identification of cancer susceptibility loci, only
four studies have performed on lung cancer outcomes (124, 126, 127, 130). GWAS on
outcomes studies has its limitations. The bottleneck is the requirement of large populations
identified from multi-institutions to provide sufficient statistical power for GWAS analysis.
And for outcome analysis, to obtain adequate clinical characteristics from all populations,
such as histology, treatment regimens, and following-up information, is the pre-requisite for
conducting such studies. Due to the heterogeneity nature of treatment regimens for lung
cancer patients as well as the lack of comparable clinical/ follow-up data, to identify a
comparable validation populations is usually a challenge, which largely hindered the

17

progress of GWAS on lung cancer outcomes (83). In this scenario, to initiate multiinstitutional collaborations for a well-designed GWAS of stage or treatment-specific
analysis of patients’ outcomes is warranted.
Meanwhile, pathway-based approaches have its unique advantage as a powerful tool for
outcome study. With limited number of candidate loci, the pathway-based approach required
a much smaller sample size, and therefore is cost-effective and much easier to identify a
validation population (132-137). Moreover, since pathway-based approaches are developed
based on prior established knowledge of disease, it provides more coverage on the specific
interested functional pathways relevant to disease, and is easier to discover gene-gene
network interactions and study complex underlying biological network (132-137). In this
context, a large scale pathway-based genetic variation study focusing on interesting
biological pathways is both necessary and desirable for outcomes studies.

1.4

MicroRNA

MicroRNAs (miRNAs) are a class of small non-coding RNAs approximately 22
nucleotides in length. Emerging evidence has shown that miRNAs function as oncogenes or
tumor suppressor genes depending on the context (138-140) and have been shown to be
potential biomarkers for cancer risk assessment, clinical treatment response, and prognosis
(141).

1.4.1

MiRNA biogenesis

MiRNAs undergo a complex processing procedure to produce the mature, functional unit.
The initial step is the generation of pri-miRNA from the miRNA gene transcript through a
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series of RNases. These pri-mRNA transcripts are then cleaved by Drosha, an RNase III
endonuclease, producing an 85-nucleotide hairpin structure termed pre-miRNA. After
exportation into the cytoplasm by Exportin-5/Ran-GTP complex, pre-miRNAs are further
processed by DICER into an 18-25 nucleotide intermediate duplex. A single strand of this
mature miRNA then becomes part of the RNA-inducing silencing complex (RISC) together
with various other proteins, such as TARBP2, AGO2, GEMIN3, and GEMIN4. This
complex then binds to the target mRNA to regulate gene function either through cleavage of
the transcript by the RISC complex or induction of translational silencing through RNARNA interactions(142). Impaired miRNA processing has been reported to reduce stable
miRNA levels and promote tumorigenesis (143), and genetic variations in several miRNA
processing genes have been reported to influence the risk of several cancers, including
bladder, esophageal and kidney cancer(144-146).
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Figure 2 The scheme of miRNA biogenesis and regulation
(147) Reprinted by permission from Macmillan Publishers Ltd: Nat Cell Biol,
copyright (2009)
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1.4.2

miRNA binding site polymorphisms

Although miRNA genes are highly conserved with very few known genetic variations in
the mature miRNA regions, the frequency of variations within miRNA target sites, which
are located in less conserved 3’ untranslated regions (UTRs), is much greater(148). Genetic
variations within these sites are of interest because single nucleotide polymorphisms (SNPs)
in the miRNA binding site may either disrupt the binding ability on an existing binding site
or create a previous non-existing binding site, thus altering normal gene expression.
Recently, there has been an increasing interest in exploring miRNA binding site
polymorphisms and their association with human diseases, ranging from mental disorders to
cancers (149). Given the significant role of miRNA regulation, the fast growth of this field
might revolutionize the way of cancer risk and prognosis prediction, and also help clinician
to tailor personalized cancer therapy.

1.4.3

miRNA and cancer

Impaired miRNA processing has been reported to reduce stable miRNA levels and
promote tumorigenesis (143). Genetic variations in several miRNA processing genes have
been reported to influence the risk of several cancers, including bladder, esophageal, kidney,
and ovarian cancers (144, 146, 150, 151). In addition, variation in miRNA binding sites
within 3’ untranslated regions (3’UTR) of target genes may also affect miRNA-mRNA
interaction and target gene expression, leading to altered cancer risk (152-157).
Evidence has shown that miRNAs are related to cancer prognosis including lung cancer.
For examples, Yanaihara et al have reported that high hsa-miR-155 and low hsa-let-7a-2
expression correlated with poor survival (141), and distinct miRNA expression profile was
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repeatedly observed between normal and tumor tissue of lung cancer patients (141, 158,
159).

1.5

Inflammation pathways

Inflammation is an important cellular process that is activated in response to tissue
damage, infections and other cellular processes (figure 2). However, a growing body of
evidence supported a relationship between inflammation and cancer, with many cancers
initiated at the site of inflammation. Products of the inflammatory response, such as free
oxygen radicals, may induce harmful DNA alterations resulting in carcinogenesis and
formation of invasive and/or metastatic phenotypes (160-165). Inflammatory cells and
related signaling molecules could also be utilized by tumor to facilitate its progression and
metastasis by generating a favorable micro-environment as well as promoting genetic
instability and angiogenesis (161).
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Figure 3inflammation pathways in response to a danger signal
(135)
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The lung is a frequent site of infection and occasional site of chronic inflammation owing
to environmental exposures. Furthermore, accumulating evidence shows that inflammation
is associated with prognosis of various cancers, including lung cancer (166-169).
Poorer survival was found in cancer patients with elevated inflammatory markers. For
example, high regulated Cox-2, which is a major enzyme involved in inflammatory response,
is found in lung cancer, and associated with immune suppression, VEGF over expression,
and also promotes angiogenesis and tumor invasions (67-70). Many studies have provided
evidence that Cox-2 expression is a prognostic factor for NSCLC (68, 170, 171). In a study
if 162 resected NSCLCs, more than 7 years difference in the median survival time was
observed between patients with highest and lowest Cox-2 expression level (170, 171). Also,
It is found that elevated circulating levels of C-reactive protein, an acute-phase reactant in
inflammatory response, were associated with poor survival in NSCLC patients (168, 169). A
few studies have explored associations between selected inflammation gene polymorphisms
and lung cancer prognosis, with inconsistent results because of small sample sizes (172,
173).
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1.6

Hypothesis and rationale

1.6.1

Hypothesis 1: miRNA-related genetic variations are associated with survival and

recurrence in NSCLC patients
MicroRNAs (miRNA) post-transcriptionally regulate over 30% of human genes, miRNA
was found de-regulated in most of human tumors. Evidence also showed miRNA are related
to lung cancer prognosis. Given its important role, in this study, we hypothesized that
miRNA-related polymorphisms, including polymorphism in miRNA processing genes, and
miRNA binding sites in major cancer-related genes, could influence various cellular
processes, such as tumor cell survival and drug response, thus have an impact on the clinical
outcomes in NSCLC patients.

1.6.2

Hypothesis 2: Genetic variations in the inflammation pathways are associated with

survival in late stage NSCLC patients
Lung cancer patients are usually diagnosed with advanced stage disease, which
commonly treated with chemotherapy combination regimens. Inflammation has a wellestablished role with carcinogenesis, and it is estimated that inflammation contributes to 15%
of cancer deaths. Evidence showed that inflammatory molecules and effectors not only
increases the risk of developing cancer, but promotes tumor progression and mediate cancer
patients’ response to treatment and prognosis . Thus, we hypothesized that polymorphisms
in major inflammation-related genes may affect inflammatory responses thus influence
survival in late stage NSCLC patients
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1.6.3

Hypothesis 3: Genetic variants in the inflammation pathway are associated with

survival in never smokers among NSCLC patients
Lung cancer in never-smokers (LCINS) is increasingly recognized as a distinct disease
from that in ever-smokers owing to substantial differences in etiology, clinical
characteristics, and prognosis. Identification of specific prognostic and predictive markers
for lung cancer in never-smokers beyond the general markers for lung cancer is warranted.
Inflammation plays an important role in cancer initiation and progression, as well as
influence clinical outcomes. In the present study, we hypothesized that inflammation-related
genetic variants could influence host gene function and inflammatory responses, thus would
have impact on NSCLC patients’ prognosis through smoking independent mechanisms.
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2.1

Study populations and data collection

MD Anderson discovery population: Patients from The University of Texas MD
Anderson Cancer Center included in this study were part of an ongoing lung study that has
been recruiting since 1995. All patients were non-Hispanic white, had histologically
confirmed (AJCC v6.) NSCLC. A structured questionnaire was used to collect
epidemiologic and demographic data during an in-person interview with each patient. In
addition, genomic DNA was extracted from peripheral blood samples obtained from each
patient using the QIAamp DNA extraction kit (Qiagen, Valencia, CA), following standard
protocol. Clinical and follow-up data were obtained from medical records. Each patient
signed an informed consent form, and this study was approved by the MD Anderson
Institutional Review Board.
Harvard University population: The details of the Harvard population have been
described in detail previously (174). In brief, this lung cancer study was initiated in 1992;
patients were recruited at the Massachusetts General Hospital. All participants in that study
were at least 18 years old white patients with a confirmed primary lung cancer. An
interviewer-administered questionnaire was used to collect epidemiologic data
(demographics, occupational exposures, smoking history) for each patient. Peripheral blood
was drawn from each patient for DNA extraction.
Mayo Clinic population: Patients at Mayo Clinic had newly diagnosed, histopathological
confirmed primary NSCLC. A structured questionnaire was used to collect detailed
epidemiological data on the patients. These patients participated in a long-term follow-up
study from 1997 to 2008 described in detail previously (175, 176). Medical records were
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reviewed for clinical and epidemiological data abstraction. All analyses were restricted to
Caucasian patients to minimize effects of population structure.

2.2

SNP selection, genotyping and quality control

2.2.1

miRNA related SNPs

Gene and SNP selection: We had previously constructed a custom Illumina iSelect chip
containing a comprehensive panel of approximately 10,000 SNPs from 998 cancer-related
genes. The detailed description of this chip, including the SNP and gene selection schema,
has been described previously (177). Eight miRNA processing genes (DDX20, DGCR8,
DICER1, RNASEN, EIF2C1, GEMIN4, RAN, and XPO5) were among the 998 genes on
this chip with 77 tagging (10 kb flanking and within each gene, linkage coefficient r2>0.8)
and potential functional SNPs genotyped. We used the PolymiRTS database (Bao, Zhou et
al. 2007) to identify SNPs in predicted binding sites for the 998 genes included on the chip
and identified a total 163 SNPs from 133 genes with these criteria. All the selected SNPs
had a minor allele frequency (MAF) greater than 0.01 in the Caucasian population. Table 3
listed the genes we selected in our study, and supplementary table 1 provides the entire list
of all SNP analyzed.
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Table 3:miRNA Processing and predicted targets genes
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Genotyping and quality control: Genomic DNA was extracted from peripheral blood
samples using the QIAamp DNA extraction kit (Qiagen, Valencia, CA) following
manufacturer’s protocol. SNPs genotyping was performed using iSelect Infinium II
genotyping platform (Illumina, San Diego, CA, USA) according to the standard Infinium II
assay protocol. Only SNPs with a cluster call rate >0.95 were included in the analysis.
DAVID gene ontology database (http://david.abcc.ncifcrf.gov/home.jsp) was used to
analyze gene function clustering.

2.2.2

inflammation related SNPs

Gene and SNP selection: Compilation of the genes involved in the inflammatory response
was performed based on a published panel of inflammation-associated genes (135) and a
database of diabetes and inflammation genes (T1DBase [http://www.t1dbase.org];
University of Cambridge, Cambridge, UK). Tagging SNPs for candidate genes based on
data from an European population were identified using data from the International HapMap
Project, based on National Center for Biotechnology Information B36 assembly and dbSNP
b126. For each gene, sequences 10 kb before the transcription start site and 10 kb after the
transcription end site were included in the tag SNP selection using the Tagger pairwise
method (Broad Institute, Cambridge, MA, USA) with an r2 threshold of 0.8 and minor allele
frequency of at least 0.05 (178). The complied SNP list was sent to Illumina (San Diego, CA,
USA) for designability analysis using their array design tool. Only SNPs that exceeded the
threshold score (>0.4) were considered designable. In total, 11,930 SNPs (supplementary
table 1) were included for construction of an Infinium II iSelect Custom Genotyping
BeadChip (Illumina).
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Table 4: Inflammation-related pathways selected
Pathway

No. of genes

No. of SNPs

Adhesion-extravasation-migration

12

108

Apoptosis signaling

67

834

Complement cascade

3

8

Cytokine signaling

266

3139

Glucocorticoid/PPAR signaling

24

258

Innate pathogen detection

53

542

Leukocyte signaling

132

2023

MAPK signaling

156

2854

Natural killer cell signaling

31

296

Phagocytosis-Ag presentation

41

488

PI3K/AKT signaling

45

580

ROS/glutathione/cytotoxic granules

25

231

TNF superfamily signaling

49

569

Total

904

11930

PPAR=peroxisome proliferator-activated receptor; MAPK=mitogenactivated protein kinase; PI3K=phosphatidylinositol 3-kinase;
ROS=reactive oxygen species; TNF=tumor necrosis factor.
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Genotyping and quality control: Genotyping for inflammation SNPs were performed at
MD Anderson Cancer Center, Mayo Clinics and Harvard University using different
platforms for discovery and validation purpose:
1)

MD Anderson: detailed genotyping and quality control methods used in the

discovery phase have been previously described (179). Briefly, genotyping was performed
according to the standard Infinium II assay protocol for the iSelect HD BeadChips
(Illumina). Quality control measures were applied to the datasets, excluding any DNA
samples or SNPs with a call rate (percentage of data available for all SNPs or samples)
<95%. For patients with direct relatives also enrolled in the study, only 1 patient within the
relationship, the one whose DNA sample had a higher SNP call rate, was included in the
final analysis. SNPs with MAF <0.01 were excluded. For validation purpose, genotyping for
SNPs selected in the discovery phase was done either through the design of a custom
Illumina Infinium iSelect BeadChip or using existing Illumina HumanHap300/
HumanHap317/ HumanHap660 genotyping data. Quality control for the Illumina Infinium
iSelect BeadChip was performed on the basis of sample and SNP call rates; we removed any
samples or SNPs with a call rate <95%. Detailed quality control measures for the Illumina
HumanHap300/HumanHap317/HumanHap660 BeadChip have been described previously;
these were also based on genotyping call rate (call rate >95% for all samples and SNPs
included). SNPs with MAF <0.01 were also excluded (180).
2)

Mayo clinics: SNPs selected for validation at Mayo Clinic were genotyped at Mayo

Clinic’s Genotyping Core Facility using a Fluidigm Dynamic Array (South San Francisco,
CA, USA) and a HumanHap317 BeadChip (Illumina) according to a standard protocol and
using quality control measures.
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3)

Harvard University: Genotyping for externally validated SNPs was performed using

the Illumina HumanHap610 chip following standard protocol, as previously described (123).
Quality control measures were similar to those used in the MD Anderson populations: only
SNPs and samples with a genotyping call rate >95% and SNPs with MAF >0.01 were
included in the analysis.

2.3

Statistical analyses

Demographic and clinical variables by vital status were selected compared using the χ2
and Fisher’s exact test. The multivariable Cox proportional hazards regression models, with
corresponding hazard ratios (HRs) and 95% confidence intervals (CIs), were used to
estimate the effect of single SNPs on overall survival (the time between diagnosis and death
or last follow-up) and progression (time from start of treatment to progression or last followup) based on the best fitting model. Kaplan-Meier survival curves and corresponding logrank tests were used to estimate the effect of each SNP on time to death. Patients who had
smoked fewer than 100 cigarettes over their lifetime were defined as never-smokers; eversmokers were defined as patients who had smoked more or equal to 100 cigarettes over their
lifetime, including former smokers (those who had quit smoking more than 1 year before
diagnosis), and current smokers and recent quitters (those who had quit smoking within a
year before diagnosis). Meta-analysis of the different populations was performed to obtain
summary HRs and 95% CIs. Heterogeneity was tested using chi-square-based Q-statistics. A
fixed-effect model was used when heterogeneity was absent (P for heterogeneity >0.05).
The cumulative effect of the top 2 validated SNPs within each population was determined
by counting the number of unfavorable genotypes (UFGs) each patient carried and using
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patients without any UFGs within that population as a reference group. All the statistical
analyses above were performing using STATA software (Stata Corporation, College Station,
TX). Survival tree analysis was performed to identify higher-order gene-gene interactions
affecting progression and/or survival using the STREE program
(http://masal.med.yale.edu/stree/). STREE uses a log-rank statistic method to select the
optimal split and subsequent split of the data set, each terminal node represented a group of
patients who had the same genotype combination and risk profile. Multiple hypothesis
testing was performed using R package with a q value (181), adjustment for multiple
comparisons was based on a false discovery rate (FDR) of 5%. Bootstrap re-sampling
method (by generating sample with duplicates for 1000 times) was used to internal validate
the associations remained significant after multiple comparison (q<0.05). In case multiple
SNPs were highly linked (R2>0.8), only one was kept for multiple SNPs analysis.
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/index.shtml) and SIFT (http://sift.bii.astar.edu.sg/) were used in silico to predict the influence of the validated missense SNP on
protein function (182, 183).

2.4

Luciferase reporter assay

Selected miRNA binding site SNPs, FAS:rs2234978 and SP1:rs17695156, were
evaluated in vitro using the dual-luciferase reporter assay. Due to the characteristics of the
genomic sequence of the 3’UTR of FZD4, this region was unable to be cloned.
Luciferase reporter constructs for wildtype and variant allele containing binding site
regions were generated. Briefly, a part of 3’UTR of each gene was amplified by PCR from
genomic DNA and then cloning restriction sites were generated by nested PCR. The FAS
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SNP (rs2234978) is located in exon 7, which serves as 3’UTR of a nonsense-mediated
mRNA decay transcript (NCBI dbSNP database; www.ncbi.nlm.nih.gov/projects/SNP).
Therefore, the entire exon sequence was generated by oligo hybridization. The PCR product
or DNA fragment was digested with XbaI and FseI restriction enzymes (New England
Biolabs, Ipswich, MA) and ligated into similarly digested pGL3 vector attached to 3’ end of
luciferase reporting gene. The variant allele containing vectors were generated by sitedirected mutagenesis. All the constructs were sequenced to ensure the correct sequence.
Primers and oligos used in reporter construct cloning are available upon request. Two lung
cancer cell lines NCI-H460 (large cell carcinoma) and NCI-H2444 (adenocarcinoma) were
cultured in RPMI-1640 medium (Mediatech, Manassas, VA) supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA) in 48-well tissue culture plates. Cells were
transfected with 0.5 mg of each reporter construct, 5 pmol of negative control (scrambled
sequence), or predicted targeting miRNAs (Sigma-Aldrich, St. Louis, MO) and 8 ng of
pGL4 (Ambion, Austin, TX) Renilla luciferase reporter using Lipofectamine 2000
(Invitrogen). After 36 hours of incubation, cell lysates were harvested and measured for
luciferase activity using the Dual-Luciferase Reporter Assay System (Promega, Madison,
WI) and a FLUOstar Optima microplate reader (BMG Labtech, Cary, NC). Each assay was
repeated independently at least two times with four replicates. The firefly luciferase activity
was normalized to the Renilla luciferase activity to derive the relative luciferase activity.
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3.1

miRNA-related genetic variations and clinical outcomes in NSCLC patients

3.1.1

miRNA-related genetic variations and survival and recurrence in early stage NSCLC

patients
3.1.1.1 Patients characteristics
This study included 535 early stage (I and II) NSCLC patients with an overall median
survival time of 90.2 months and median follow-up time of 62.1 months. Characteristics of
the study population are shown in Table 5. Mean ages for surgery-only and surgery plus
chemotherapy treated patients were 65.8 years and 62.9 years, respectively. At the time of
analysis, 322 (60%) of the patients were alive and 360 (67%) did not have a progression of
their disease. Nearly equal numbers of male and female participants were included (49% and
51% respectively) with a majority of the study population consisting of Caucasian patients
(88%). The clinical stage distribution is stage IA (46%), stage IB (35%), stage IIA (5%) and
stage IIB (14%). A majority of the NSCLC cases were adenocarcinomas (59%) with 28%
squamous cell carcinoma and the remaining 13% unclassified or other NSCLC. Of the 535
participants, 340 patients received surgery-only, 127 patients were treated with surgery plus
neoadjuvant and/or adjuvant chemotherapy, and the remainder (68 patients) treated with
only radiation therapy with/without surgery.
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Table 5: Host characteristics of early stage NSCLCs
Variables
Total Patients
Median survival time(mos)
Median follow-up time(mos)
Age, mean(sd)
Gender
Male
Female
Ethnicity
Caucasian
African-American
Others
Pack year, mean(sd)
Histology
Adenocarcinoma
Squamous cell carcinoma
Unclassified or other
Clinical stage
Stage IA
Stage IB
Stage IIA
Stage IIB
Treatment
Surgery only
Surgery & other treatment
Treatment without surgery
Surgery result
Complete
Residual
Vital status
Alive
Dead
Progression
No
Yes

All early stage
No. of patients (%)
535
90.2
62.1
65.7(10.1)

Surgery only
No. of patients (%)
340
102.0
71.6
65.8(9.9)

Surgery & chemo
No. of patients (%)
127
118.3
50.7
62.9(10.2)

262(49)
273(51)

166(49)
174(51)

68(54)
59(46)

469(88)
42(8)
24(4)
44.9(36.6)

305(90)
25(7)
10(3)
45.1(37.6)

109(86)
10(8)
8(6)
39.4(35.2)

315(59)
149(28)
71(13)

213(63)
87(26)
40(12)

74(58)
34(27)
19(15)

245(46)
188(35)
26(5)
76(14)

181(53)
113(33)
10(3)
36(11)

23(18)
55(43)
14(11)
35(28)

340(64)
142(27)
53(10)

340(100)
N/A
N/A

N/A
127(100)
N/A

470(98)
12(2)

340(100)
N/A

123(97)
4(3)

213(40)
322(60)

210(62)
130(38)

88(69)
39(31)

360(67)
175(33)

233(69)
107(31)

85(67)
42(33)
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3.1.1.2 Associations between individual SNPs and NSCLC clinical outcomes
Among all the variants analyzed, 11 processing and 23 binding site SNPs were
significantly associated with altered risk of dying. The most significant association with
survival for early stage NSCLC was FAS:rs2234978 (HR:0.59, 95% CI:0.44-0.77,
P=1.67×10-4, q=0.018), which remained significant after multiple comparison corrections,
and resulted in a significant increase in median survival time (MST) from 59 to 118 months
(log rank P=1.0×10-4; Figure 4a).
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Figure 4 Kaplan-Meier estimates of FAS:rs2234978 on overall survival:
(a) total population; (b) surgery-only patients; (c) surgery plus chemotherapy patients. MST:
median survival time in months. N=A/B, A: number of patients with event, B: total number
of patients.
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Five SNPs in processing genes and 23 SNPs in binding sites were significantly
associated with time to progression. The most significant association, which remained
significant after correcting for multiple comparisons, was SP1:rs17695156 (HR:2.22,
95%CI:1.44-3.41, P=3.00×10-4, q=0.034). Patients with at least one variant allele had more
than 224 months decreased median progression-free time compared to patients who had
common homozygous genotype (45.3 months vs >270 months, log rank P=7.0×10-4, Figure
5).

Figure 5 Kaplan-Meier estimates on effect of SP1:rs17695156 on time to progression
among early stage patients.
MPFT: median progression-free time in months. N=A/B, A: number of patients with event,
B: number of all patients.
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3.1.1.1 Effects of treatments on association of clinical outcomes
Different treatment regimens may function through different mechanisms to affect
clinical outcomes. We performed subgroup analysis focusing on two groups of patients with
relatively homogeneous treatment regimens: surgery-only and surgery plus chemotherapy.

Effect on overall survival
Eighteen SNPs were significantly associated with overall survival in surgery-only
patients. FZD4:rs713065 (HR:0.46, 95% CI:0.32-0.65, P=2×10-5, q=0.002), located in the 3’
UTR of FZD4, remained significant after adjustment for multiple comparisons. Patients with
at least one variant allele have significantly decreased risk of death and increased MST from
59 to 117 months compared those patients with the common genotype(log rank P=1.05×10-5;
Figure 6a). Notably, in agreement with the overall population, for patients who received
surgery plus chemotherapy, FAS:rs2234978 (HR:0.19, 95% CI:0.07-0.46, P=1.84×10-5)
displayed the most significant association with survival. Patients with at least one variant
allele had 81% lower risk of death (HR:0.19, 95% CI:0.07-0.46) with their MST increased
by 2-fold, compared to patients who carry the homozygous common genotype (65 months
vs. 137 months, log rank P=1.05×10-4, Figure 4c). The association of this SNP with survival
was borderline significant after correction for multiple comparisons in surgery-only patients
(HR:0.59, 95% CI:0.42-0.84, P=0.004, q=0.069), with increased median survival time (61
months vs. 102 months, log rank P=4.02×10-3, Figure 4b).
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Figure 6 Kaplan-Meier estimates of effect of FZD4:rs713065 on overall survival
(a) total population; (b) surgery-only patients. (c) surgery plus chemotherapy patients. MST:
median survival time in months. N=A/B, A: number of patients with event, B: total number
of patients.
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By comparing the findings between two subgroups, we identified two distinct clusters of
SNPs that showed statistically significant association with survival in only one specific
treatment subgroup. Seventeen SNPs (13 binding site and 4 processing SNPs) were found to
have significant effects on risk of dying in surgery-only patients but no significant
associations with survival in patients receiving surgery plus chemotherapy. In contrast, 28
SNPs (18 binding site and 10 processing SNPs) were found to be significantly associated
with risk of death only in patients receiving surgery plus chemotherapy, but not in surgeryonly patients. Intriguingly, within each cluster of SNPs, we identified SNPs with differential
directions of their effect. A group of 29 SNPs has the same trend in both treatment
subgroups (either protective or adverse), while 15 SNPs conferred opposite effects between
two subgroups (Table 6). For example, FZD4:rs713065 was associated with significantly
decreased risk of dying and prolonged survival time in surgery-only patients; however, in
the surgery plus chemotherapy subgroup, this SNP was associated with increased risk of
dying and a shortened median survival time (Figure 6b and 6c). Significant dose-dependent
effects on risk of dying were identified in the two treatment subgroups with patients carrying
increased number of UFGs showing a significant trend toward poorer survival and shortened
median survival time (P for trend<1×10-4, Figure 7a and 7b).
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Table 6: Effect of selected SNPs on survival in early stage NSCLC patients
Gene

SNP

Curative Intent
HR (95%CI)**

P

Surgery-only
HR (95%CI)**

rs2234978
0.59(0.44-0.77)
2×10-4*
0.59(0.42-0.84)
rs713065
0.68(0.51-0.90)
0.46(0.32-0.65)
0.01
rs854552
1.94(1.29-2.92)
2.29(1.36-3.88)
2×10-3
rs3790611
1.62(0.97-2.71)
0.06
2.60(1.39-4.86)
rs197412
1.66(1.18-2.32)
1.87(1.24-2.82)
3×10-3
rs12954944
1.52(1.07-2.16)
1.74(1.14-2.65)
0.02
rs11089328
1.38(0.96-1.98)
0.08
1.79(1.14-2.79)
rs3747238
1.55(1.11-2.16)
1.77(1.17-2.68)
0.01
rs872396
1.50(1.08-2.09)
1.79(1.17-2.75)
0.02
rs1048691
0.43(0.21-0.89)
0.31(0.11-0.86)
0.02
rs7719666
0.87(0.72-1.06)
0.16
0.74(0.57-0.96)
rs1043180
1.50(1.07-2.10)
1.63(1.07-2.47)
0.02
rs12010722
0.83(0.67-1.03)
0.08
0.73(0.55-0.97)
rs4988514
0.75(0.51-1.10)
0.15
0.60(0.37-0.98)
rs7669660
0.78(0.56-1.08)
0.13
0.63(0.41-0.97)
rs1131636
0.94(0.77-1.15)
0.57
0.75(0.58-0.98)
rs15864
0.82(0.65-1.02)
0.08
0.75(0.56-0.99)
rs7695605
1.28(0.97-1.70)
0.09
1.44(1.01-2.05)
rs1047312
1.15(0.98-1.35)
0.08
1.08(0.88-1.32)
rs669702
1.26(0.91-1.75)
0.16
1.08(0.71-1.66)
rs1133043
1.13(0.75-1.69)
0.56
0.67(0.37-1.21)
rs3172417
0.90(0.62-1.32)
0.59
0.71(0.42-1.19)
rs7245
1.08(0.78-1.50)
0.64
0.83(0.52-1.31)
rs12125947
1.22(0.99-1.49)
0.06
1.15(0.88-1.52)
rs1425486
1.43(1.06-1.93)
1.18(0.81-1.71)
0.02
rs9532558
1.71(0.79-3.68)
0.17
1.44(0.52-4.04)
rs17330637
1.57(1.04-2.38)
1.15(0.64-2.08)
0.03
rs3747240
1.29(0.94-1.77)
0.12
1.08(0.69-1.69)
TNFRSF10D
rs7957
1.24(0.92-1.65)
0.15
1.01(0.69-1.49)
RPS6KB2
rs10274
0.83(0.68-1.02)
0.08
0.85(0.66-1.10)
FZD3
rs352222
0.82(0.68-1.00)
0.86(0.67-1.09)
0.05
DROSHA
rs10035440
1.01(0.76-1.34)
0.95
1.27(0.89-1.82)
IGF2BP1
rs6504593
1.30(0.94-1.80)
0.11
1.24(0.83-1.87)
DROSHA
rs673019
1.27(0.92-1.77)
0.15
1.25(0.81-1.95)
SP1
rs17695156
1.52(1.03-2.24)
1.20(0.68-2.13)
0.03
RAN
rs10848238
1.40(1.06-1.86)
1.19(0.82-1.72)
0.02
PMS2L3
rs1167829
0.86(0.68-1.10)
0.24
0.97(0.72-1.31)
DROSHA
rs639174
0.96(0.56-1.66)
0.89
0.80(0.39-1.65)
DROSHA
rs2302905
1.04(0.78-1.39)
0.81
0.91(0.62-1.33)
MDM4
rs10900596
1.31(1.05-1.63)
1.29(0.97-1.72)
0.02
ICAM1
rs281437
1.44(1.09-1.89)
1.38(0.96-1.98)
0.01
DICER1
rs1187642
1.35(0.91-2.01)
0.14
1.00(0.58-1.73)
DGCR8
rs2073778
0.78(0.54-1.11)
0.16
0.89(0.57-1.39)
DGCR8
rs720012
0.76(0.53-1.09)
0.13
0.89(0.56-1.41)
RAN
rs11061209
1.50(1.14-1.98)
1.44(1.00-2.05)
4×10-3
DNMT3B
rs6058896
1.39(0.93-2.07)
0.11
1.59(0.88-2.89)
* Remain significant after multiple comparisons using FDR of 5%
**Adjusted by age, gender, ethnicity, stage, pack year and treatment regimens.
FAS
FZD4
PON1
WNT2B
DDX20
ATP5A1
DGCR8
SMC1L2
RAN
CDK4
DROSHA
NEIL2
RPS6KA3
SST
ADH5
RPA1
GSTM3
TLR2
SULT1C1
DROSHA
GPR30
FANCD2
NDUFA6
CDC7
PDGFC
FOXO1A
BIRC4
SMC1L2
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P
4×10-3
2×10-5*
2×10-3
3×10-3
3×10-3
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.03
0.04
0.04
0.04
0.04
0.05
0.45
0.72
0.19
0.19
0.42
0.3
0.39
0.48
0.64
0.73
0.94
0.21
0.21
0.19
0.3
0.31
0.53
0.36
0.84
0.55
0.62
0.07
0.08
0.99
0.61
0.62
0.05
0.13

Surgery & chemotherapy
HR (95%CI)**
P
0.19(0.07-0.46)
1.50(0.71-3.19)
2.00(0.87-4.60)
0.45(0.09-2.11)
0.97(0.32-2.98)
0.60(0.20-1.87)
0.90(0.31-2.62)
0.96(0.37-2.47)
1.28(0.57-2.85)
1.33(0.38-4.63)
1.09(0.68-1.74)
1.39(0.63-3.06)
0.91(0.54-1.53)
1.16(0.48-2.80)
1.00(0.43-2.34)
0.77(0.47-1.27)
0.96(0.50-1.86)
1.58(0.80-3.13)
2.01(1.30-3.10)
3.49(1.59-7.64)
3.57(1.55-8.21)
3.32(1.41-7.81)
2.76(1.29-5.88)
1.90(1.14-3.17)
3.13(1.39-7.06)
9.03(1.85-44.1)
2.79(1.25-6.25)
2.59(1.30-5.19)
2.55(1.23-5.29)
0.51(0.30-0.87)
0.46(0.25-0.82)
0.37(0.16-0.88)
2.90(1.16-7.28)
2.40(1.13-5.08)
2.44(1.13-5.29)
2.15(1.11-4.17)
0.44(0.22-0.86)
2.86(1.09-7.49)
2.25(1.11-4.58)
1.66(1.04-2.66)
2.20(1.10-4.39)
2.61(1.09-6.27)
0.30(0.10-0.88)
0.30(0.10-0.90)
2.13(1.04-4.36)
2.37(1.00-5.59)

3×10-4*
0.29
0.10
0.31
0.96
0.38
0.84
0.93
0.55
0.65
0.73
0.42
0.72
0.75
0.99
0.30
0.91
0.19
2×10-3
2×10-3
3×10-3
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.04
0.05

Figure 7 Kaplan-Meier estimates of overall survival and time to progression in early
stage NSCLC patents grouped by the number of unfavorable genotypes (UFG)
(a) estimates for survival in surgery-only patients; (b) estimates for survival in patients
receiving surgery plus chemotherapy; (c) estimates for time to progression in surgery-only
patients; (d) estimates for time to progression in patients receiving surgery plus
chemotherapy; MST: median survival time in months. MPFT: median progression-free time
in months. N=A/B, A: number of patients with unfavorable event, B: total number of
patients in subgroup.
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Effect on progression
In the subgroup analysis of treatment regimen for progression risk, SP1:rs17695156,
which is the top SNP associated with progression in the combined population, was the most
significant association with progression in surgery plus chemotherapy group with a
borderline significant q value (HR:3.36, 95% CI:1.62-6.69, P=1.10×10-3, q=0.089) (Table 7).
One processing SNP, DROSHA:rs6886834 was significantly associated with more than 6
times increased risk for progression in surgery-only patients (HR:6.38, 95%CI:2.49-16.31,
P=1.10×10-4, q=0.011) (Table 7). Patients who carried at least one variant allele of this SNP
had significant reduction in progression-free time compared with patients with common
homozygous genotype (23 months vs >270 months, log rank P=5.0×10-4; Figure 8).This
association remained significant after correction for multiple comparisons (Table 7).
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Table 7: Effect of selected SNPs on progression in early stage NSCLC patients
Curative Intent
Surgery-only
SNP
Model
HR (95%CI)**
P
HR (95%CI)**
P
rs6886834
REC
2.28(1.20-4.32)
6.38(2.49-16.31)
0.012
1.1×10-4*
rs11663629
DOM
1.67(1.12-2.50)
2.33(1.35-4.02)
0.012
0.002
rs2453994
DOM
1.44(1.01-2.05)
2.07(1.24-3.46)
0.041
0.006
rs11061209
REC
1.38(0.84-2.28)
0.201
2.40(1.25-4.61)
0.008
rs1633445
ADD
1.28(0.96-1.71)
0.088
1.66(1.14-2.42)
0.009
rs8946
DOM
1.40(0.96-2.04)
0.084
2.20(1.21-4.00)
0.010
rs502267
REC
3.11(1.29-7.51)
0.012
rs12125947
REC
1.91(1.27-2.88)
2.07(1.17-3.67)
0.002
0.012
rs4246215
DOM
0.75(0.52-1.08)
0.118
0.51(0.29-0.88)
0.017
rs10770125
DOM
0.77(0.53-1.11)
0.161
0.54(0.32-0.90)
0.020
rs3757
ADD
1.28(0.95-1.71)
0.099
1.59(1.08-2.34)
0.020
rs1133026
DOM
1.53(1.07-2.18)
1.81(1.09-3.00)
0.020
0.022
rs3790611
REC
1.87(0.99-3.52)
0.052
2.79(1.15-6.73)
0.023
rs2248718
DOM
1.29(0.88-1.88)
0.195
1.81(1.09-3.02)
0.023
rs7712155
REC
1.63(0.75-3.57)
0.218
2.94(1.16-7.45)
0.023
rs12186785
DOM
1.77(1.15-2.71)
1.94(1.09-3.45)
0.009
0.024
rs15864
REC
0.32(0.11-0.87)
0.19(0.05-0.81)
0.025
0.025
rs10035440
DOM
0.71(0.48-1.06)
0.091
0.50(0.27-0.92)
0.025
rs107822
DOM
0.82(0.57-1.17)
0.269
0.54(0.31-0.93)
0.027
rs720014
ADD
1.25(0.93-1.67)
0.136
1.54(1.04-2.27)
0.031
rs1042927
DOM
1.27(0.78-2.06)
0.339
2.06(1.06-3.98)
0.032
rs3747238
DOM
0.78(0.53-1.14)
0.195
0.57(0.34-0.96)
0.036
rs2287584
REC
0.91(0.44-1.89)
0.801
2.40(1.05-5.52)
0.039
rs174546
DOM
0.77(0.54-1.11)
0.159
0.58(0.34-0.98)
0.042
rs197412
REC
1.31(0.83-2.08)
0.249
1.85(1.01-3.38)
0.045
rs1048201
DOM
1.22(0.82-1.81)
0.325
1.72(1.01-2.92)
0.047
rs3917328
DOM
0.63(0.32-1.26)
0.193
0.35(0.12-0.99)
0.048
rs2710625
ADD
0.85(0.66-1.09)
0.207
0.69(0.48-0.99)
0.049
rs17695156
DOM
2.22(1.44-3.41)
3x10-4*
1.56(0.77-3.17)
0.213
rs1127687
DOM
1.61(1.12-2.29)
1.40(0.83-2.37)
0.212
0.009
rs669702
DOM
1.41(0.94-2.13)
0.099
1.39(0.78-2.48)
0.261
rs10787498
ADD
0.85(0.66-1.11)
0.233
0.97(0.67-1.40)
0.871
rs10913632
DOM
1.77(1.14-2.73)
1.39(0.70-2.76)
0.349
0.011
rs197377
DOM
1.36(0.95-1.96)
0.096
1.13(0.65-1.95)
0.663
rs17452383
DOM
1.09(0.73-1.62)
0.682
0.77(0.41-1.43)
0.405
rs3742330
DOM
0.53(0.29-0.95)
0.77(0.36-1.63)
0.494
0.033
rs8006416
DOM
0.53(0.29-0.96)
0.80(0.38-1.70)
0.559
0.037
rs10900596
REC
1.70(0.99-2.91)
0.054
0.83(0.31-2.20)
0.706
rs281437
DOM
1.56(1.09-2.23)
1.30(0.78-2.16)
0.306
0.015
rs10274
REC
0.54(0.31-0.94)
0.74(0.37-1.48)
0.398
0.030
rs5005121
DOM
1.10(0.62-1.94)
0.746
0.67(0.30-1.48)
0.320
rs10779765
REC
1.20(0.70-2.03)
0.507
1.00(0.46-2.14)
0.992
rs7245
REC
1.19(0.79-1.80)
0.413
0.81(0.42-1.56)
0.525
TNFRSF10D
rs7957
DOM
1.45(1.01-2.07)
1.59(0.96-2.63)
0.073
0.044
* Remain significant after multiple comparisons using FDR of 5%
**Adjusted by age, gender, ethnicity, stage, pack year and treatment regimens.
Gene
DROSHA
MBD1
ATP6V1C1
RAN
DGCR8
BAG3
DROSHA
CDC7
FEN1
IGF2AS
DGCR8
HSPB8
WNT2B
ATP6V1C1
DROSHA
DROSHA
GSTM3
DROSHA
RING1
DGCR8
RRM1
SMC1L2
DROSHA
FEN1
DDX20
FGF2
IL1R1
BIRC6
SP1
CASP7
DROSHA
CASP7
ANGPTL1
DDX20
ARNTL
DICER1
DICER1
MDM4
ICAM1
RPS6KB2
RRM2B
MTHFR
NDUFA6
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Surgery & chemotherapy
HR (95%CI)**
P
1.33(0.60-2.96)
1.10(0.53-2.28)
0.87(0.29-2.62)

0.487
0.793
0.804

1.19(0.57-2.45)

0.644

2.10(0.92-4.79)
1.21(0.61-2.40)
1.17(0.56-2.43)

0.079
0.579
0.673

1.67(0.83-3.37)

0.148

0.67(0.28-1.59)

0.362

1.33(0.54-3.25)
0.53(0.06-4.26)
1.33(0.66-2.68)
1.41(0.72-2.74)

0.531
0.547
0.425
0.313

0.53(0.20-1.38)
1.03(0.49-2.16)
0.44(0.10-2.01)
1.30(0.66-2.54)
1.20(0.45-3.18)
0.74(0.37-1.50)
1.48(0.44-5.01)
1.03(0.66-1.62)
3.36(1.62-6.96)
3.15(1.58-6.30)
2.93(1.39-6.20)
0.50(0.30-0.86)
2.61(1.20-5.67)
2.21(1.16-4.18)
2.32(1.15-4.68)
0.18(0.04-0.76)
0.18(0.04-0.76)
2.49(1.14-5.44)
2.20(1.11-4.36)
0.29(0.10-0.86)
2.79(1.13-6.88)
2.62(1.05-6.53)
2.12(1.04-4.35)
2.09(1.03-4.23)

0.191
0.931
0.290
0.445
0.716
0.408
0.528
0.895
0.001
0.001
0.005
0.012
0.015
0.015
0.019
0.020
0.020
0.022
0.023
0.025
0.026
0.038
0.040
0.040

Figure 8 Kaplan-Meier estimates on effect of DROSHA:rs6886834 on early stage
progression among surgery-only patients
MPFT: median progression-free time in months. N=A/B, A: number of patients with event,
B: total number of patients in subgroup.
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When comparing results of subgroup analysis, 28 SNPs (14 in binding sites and 14 in
processing genes) and 16 SNPs (12 in binding sites and 4 in processing genes) were
exclusively associated with altered risk for progression in surgery-only patients or surgery
plus chemotherapy patients, respectively. Of these, 19 SNPs showed the same direction of
the effects in both subgroups while 17 SNPs were found to have opposite effects in both
subgroups (Table 7). For example, in patients received surgery plus chemotherapy,
RRM2B:rs5005121 was associated with significantly increased risk for developing
progressive disease and a shortened progression-free time, but in surgery-only patients, this
SNP showed a protective effect against progression with an increased time to progression
(Figure 6). We also observed a significant cumulative effect for each group of SNPs on
modulating risk of progression - with increased number of UFGs, there is a gradual trend of
increased risk for progression and corresponding shortened progression-free timein surgeryonly and surgery plus chemotherapy subgroups (P for trend<1×10-4, Figures 9c and 9d).
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Figure 9 Kaplan-Meier estimates for the effect of RRM2B:rs5005121 genotypes on
NSCLC progression in two treatment subgroups based on the dominant model:
(a) surgery-only patients; (b) surgery plus chemotherapy patients. MPFT: median
progression-free time in months. N=A/B, A: number of patients with event, B: number of
patients in subgroup.
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3.1.1.3 Survival tree analysis of SNPs associated with NSCLC survival
Figure 10 shows the survival-tree structure identifying potential higher-order gene-gene
interactions among miRNA-related genes in modulating overall survival. SNPs that
displayed at least borderline significant association with survival after multiple comparison
adjustment (q<0.1) were included in the analysis. The terminal nodes from the analyses were
able to classify patients into three risk groups with significantly different survival
probabilities. The MSTs based on these groupings varied from greater than 86 months for
the low risk group to 41.7 months in the high risk group (log rank P<0.0001) in surgery-only
patients, and from more than 118 months to 36.8 months for low and high risk groups
respectively (log rank P<0.0001) in patients receiving surgery plus chemotherapy. Moreover,
the initial split in the tree structure for each subgroup, FZD4:rs713065 and FAS:2234978,
were also the two SNPs that remained significant after multiple comparison correction in the
two treatment subgroup analyses. Because of the limited number of SNPs that were at least
borderline significant after adjustment for multiple comparisons in the progression analysis,
survival tree analysis was not performed for this endpoint.
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Figure 10 Potential gene-gene interactions among SNPs identified in the survival
analysis in early stage NSCLC patients
(a) Survival tree analysis showing higher-order gene-gene interactions; (b) Kaplan-Meier
curves of survival time for surgery-only patients in three risk groups identified by the
survival tree analysis; (c) Kaplan-Meier curves of survival time for surgery plus
chemotherapy patients among the three risk groups. MST: median survival time in months.
N=A/B, A: number of patients with event, B: total number of patients.
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3.1.1.4 Internal validation using bootstrap re-sampling method
In order to further validate our results and to exclude potentially false positive
associations, a bootstrap re-sampling method was also used to examine the associations that
remained significant after correcting for multiple comparisons. For each SNP, we used
bootstrap re-sampling. All the SNPs that were significant after multiple comparisons at an
FDR of 5% remained significant in the bootstrap analysis for at least 450 out of 500 resamplings. Among them, two SNPs (FZD4:rs713065 in analysis of overall survival in
surgery only subgroup; SP1:rs17695156 in progression analysis of all early stage patients)
reached P<0.05 for each of the 500 iterations. FAS:rs2234978 reached P<0.01 for 500
iterations in analysis of overall survival in all early stage patients, this finding was consistent
in the surgery plus chemotherapy subgroup as well with over 65% of the re-sampled datasets
remaining significant at P<0.01. Bootstrap re-sampling analysis was also performed for
unfavorable genotype and survival tree analyses. The results were significant in all the
subgroups analysis for entire 500 re-samplings at P<0.05.

3.1.1.5 The effect of selected miRNA binding site variants on miRNA-regulation
Since several SNPs located within predicted miRNA binding sites were significantly
associated with clinical outcomes after correction for multiple comparisons, we then
performed luciferase reporter assays to determine whether these predicted binding site
variants truly result in altered miRNA regulation. FAS:rs2234978, which was consistently
associated with a beneficial effect on prognosis, was predicted to create a new miRNA
binding site in FAS for miR-561. Thus, we expected to observe a decrease in luciferase
activity for variant allele-containing construct in the presence of miR-561. In both lung
cancer cell lines, a significant decrease of luciferase signal was observed when miRNA-561
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was transfected with variant allele-containing reporter (T) (NCI-H460:P=0.029, Figure 8a;
NCI-H2444:P=0.025, Figure 11b), but not observed with wildtype allele (C) construct
(P>0.5). Comparison of the luciferase activities between co-transfections of miRNA-561
with the variant allele-containing and the wildtype-containing constructs also showed
significant difference (NCI-H460:P=0.002, Figure 11a; NCI-H2444:P=0.004, Figure 11b).
SP1:rs17695156 was predicted to disrupt a conserved miRNA site; however, in our in vitro
assays the miRNA-induced suppression of luciferase activity was observed in both variant
and wildtype allele-containing constructs co-transfected with miRNA-545. There was no
significant difference in reporter activities between the two alleles and the extent of signal
decrease varied between cell lines (data not shown).
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Figure 11 Effect of the FAS variant allele on miR-561 targeting and luciferase reporter
expression:
(a) Relative luciferase reporter activity of the wildtype and variant FAS allele in the presence
of control (Ctrl) or miR-561 in lung cancer cell line NCI-H460; (b) Relative luciferase
reporter activity of the wildtype and variant FAS allele in the presence of control (Ctrl) or
miR-561 in lung cancer cell line NCI-H2444.
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3.1.2

miRNA-related genetic variations and survival in late stage NSCLC patients

3.1.2.1 Patients characteristics
598 stage III and stage IV patients were identified in our study. Around half of all the
patients had a adenocarcinoma histology, and majority patients are ever smokers (81%).
Around 56% of all patients have been treated with any form of chemotherapy. Median
survival time for late stage patients are 11.8 months. Between vital groups (dead vs. alive),
at the time of this analysis, there are significant differences in the distribution of gender (P
=0.002), clinical stage (P =0.004), and performance status (P =0.001), all of which have
been included in the adjustment for multi-variant analysis. Histology, ethnicity, smoking
status, and age were not significant different between patients who have died and still alive.
(Table 8)
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Table 8: Host characteristics of late stage NSCLCs
Variables
Total Patients
Age, mean(sd)
Gender
Male
Female
Ethnicity
Caucasian
African-American
Others
Pack year, mean(sd)
Smoking status
Never
Former
Current & RQ
Histology
Adenocarcinoma
Squamous cell ca
Unclassified/other
Clinical stage
Stage IIIA
Stage IIIB(dry)
Stage IIB(wet)
Stage IV
Performance status
0
1
2-4
missing

Dead, No (%)

Alive, No (%)

P-value

456
59.6(10.0)

142
59.7(10.6)

0.884

262(57)
194(43)

61(43)
81(57)

0.002

358(79)
72(16)
26(6)
37(31)

112(79)
23(16)
7(5)
37(30)

0.940
0.925

84(18)
184(40)
188(41)

28(20)
59(42)
55(39)

0.860

231(51)
88(19)
137(29)

73(51)
37(26)
32(23)

0.246

57(13)
100(22)
25(5)
274(60)

25(18)
42(30)
14(10)
61(43)

0.004

96(21)
254(56)
66(14)
40( 9)

47(33)
80(56)
8( 6)
7( 5)

0.001
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3.1.1.6 Associations between individual SNPs and late stage patients survival
All 240 SNPs have been analyzed with survival in the 598 late stage NSCLC patients, 9
processing and 17 binding site SNPs were significantly associated with survival. The top
SNP was rs15561 (HR=1.70, 95%CI=1.22-2.36), in predicted miRNA binding site of gene
NAT1. The most significant processing gene SNP is rs7735863 (HR=1.38, 96%CI=1.1-1.74),
an intronic SNP in DROSHA. However, none SNP remained significant after correcting
multiple comparisons.
When comparing the SNPs remained significant after multiple comparison correction
identified in early stage patients, rs713065 was significant associated with decreased risk for
death in the late stage patients (HR=0.78, 95%CI=0.64-0.94). However, this association has
not passed the multiple comparison criteria.
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3.1.1.7 Associations between individual SNPs and survival in late stage patients treated with
chemotherapy
Because the majority of patients have been treated with chemotherapy, we then
performed a subgroup analysis focusing on patients treated with chemotherapy. A total of 24
SNP (20 binding site, 4 processing gene) were significantly associated with survival in this
subgroup, among them five binding site SNPs remained significant after correcting for
multiple comparisons (Table 9).
The most significant SNP was rs4796033 (HR=1.41, 96%CI=1.13-1.75), which is in
RAD51L3. Patients had at least one variant of this SNP had around 8 month shortened MST
(log-rank P= 3.2×10-4, Figure 12a).
Interestingly, rs15561 (HR=1.98, 96%CI=1.32-2.94), which is the top SNPs in the overall
late stage patients, remained significant after correcting for multiple comparisons. This SNP
was also significantly associated with an altered survival time – patients carrying
homogeneous variant genotype have six month shorter MST compared to those who have
common allele (log-rank P= 6.4×10-3, Figure 12b). Another NAT1 SNP rs4986993 remained
significant after multiple comparisons, which is in highly linked with rs15561 (R2=1.00).
Rs10278782 (HR=1.58, 96%CI=1.21-1.06), in gene CAV2, was also significant after
multiple comparison corrections. Also, compared to patients carrying at least one variant
allele, those patients with two variants allele have around 4 months shortened survival time
(Log-rank P=6.6×10-3, Figure 12c). Rs17749202 (HR=2.03, 96%CI=1.29-3.17), binding
sites SNP in WNT11, showed a significant risk effect after multiple comparison corrections,
patients had a GG genotype had 5 month shortened median survival time compare to those
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carrying at least one A allele, and the difference was significant (Log-rank P=0.016, Figure
12c)
In the UFG analysis, significant cumulative effect was also observed for the four
(removed rs4986993) SNPs, with increased in the number of UFG patients carries, a
progressively increased risk was observed (P for trend =2.36×10-7). Patients had at least two
UFGs had nearly four-fold increased risk for death (P=1.6×10-11) with a 9.2 month median
survival time, compared to 21.6 month of patients without any UFG (Log-rank P=6.1×10-8).
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Table 9: Selected SNPs with survival in late stage NSCLC patients
Gene

SNP

Model

HR(95%CI)

P-value

Q-value

RAD51L3

rs4796033

DOM

1.93(1.42-2.63)

2.86×10-5*

0.003

NAT1

rs15561

REC

1.98(1.32-2.94)

8.36×10-4*

0.025

NAT1

rs4986993

REC

1.98(1.32-2.94)

8.36×10-4*

0.025

CAV2

rs10278782

DOM

1.58(1.21-2.06)

7.05×10-4*

0.025

WNT11

rs17749202

REC

2.03(1.29-3.17)

2.01×10-3*

0.047

* Remain significant after multiple comparisons using FDR of 5%
**Adjusted by age, gender, clinical stage, and performance status.
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Figure 12 Kaplan-Meier estimates for the effect of selected SNPs on NSCLC survival in
patients treated chemotherapy:
(A) RAD51L3:rs4796033; (B) NAT1:rs15561; (C) CAV2:rs10278782; (D)
WNT11:rs17749202. MST: median survival time in months. N=A/B, A: number of patients
with event, B: number of patients in subgroup.
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3.1.1.8 Internal validation using bootstrap re-sampling method
We then also adopted a bootstrap re-sampling method was to further examine the
associations that remained significant after correcting for multiple comparison at an FDR of
5%. For these five each SNP and also UFG analysis, we did bootstrap re-sampling for 500
times with duplicates. All the SNPs that were significant after multiple comparisons
remained significant in the bootstrap analysis for at least 465 out of 500 re-samplings at a Pvalue less than 0.05.

3.1.2

Discussion

In this study, we identified genetic variants in miRNA processing genes and binding sites
for cancer-related genes that modulated overall survival and progression in early stage
NSCLC patients. Because majority of late stage patients have metastatic disease at the time
of diagnosis, thus analysis was only performed on survival for late stage patients. Panels of
treatment subgroup-specific predictive markers were identified and the significance of top
associations in our study was confirmed by controlling for false discoveries through multiple
comparison corrections and internal validation. FAS: rs2234978 was identified as a potential
prognostic factor in our results and functional data provides evidence that this SNP alters
miRNA regulation of FAS. These results suggested that identified genetic variants in
miRNA processing genes and miRNA binding sites may serve as potential prognostic
markers for patients’ clinical outcomes and predictive markers of response to treatment for
future investigation and clinical applications.
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Several studies have identified associations between polymorphisms in miRNA-binding
sites and human disease, including cancer (149, 184, 185). In the current study, we identified
miRNA-binding site SNPs that significantly modulated risk of either death or progression.
Specifically, FAS:rs2234978 was observed to be significantly associated with decreased risk
of death. We found a reduction in risk of dying in surgery only patients who carried the
variant allele of this SNP. This protective effect was even stronger in patient treated with
surgery plus chemotherapy. Moreover, its appearance at the top of the tree structure in the
survival tree analysis also confirmed this locus as an important marker responsible for the
largest proportion of the variation in predicting patient’s overall survival. These consistent
associations highlighted the potential importance of this SNP in modulating NSCLC risk of
dying and its potential prognostic role. FAS (member 6 of TNF receptor superfamily) is a
cell-surface receptor of the tumor necrosis family which plays an important role in the
regulation of apoptosis signaling. Interestingly, rs2234978 is a synonymous SNP located in
the seventh exon of FAS on chromosome 10q23. Typically, miRNA binding sites are located
in 3’UTRs, which for FAS is located in exon 9 of the full length transcript. However,
alternative splicing of FAS results in several transcribed isoforms that are involved in
nonsense-mediated mRNA decay (NMD), including the transcript where exon 7 serves as
the 3’UTR. NMD plays important roles in limiting the synthesis of truncated or mutant
proteins which can negatively regulate the apoptosis mediated by the full length protein as
well as global gene expression (NCBI dbSNP database). The nucleotide change from this
polymorphism is predicted to create a new miRNA binding site for miR-561, resulting in
decreased expression of the FAS alternative transcripts. We validated this function in vitro
by luciferase assay in two lung cancer cell lines. Since the NMD transcripts may negatively
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regulate normal FAS expression, this would ultimately result in increased level of FAS in
tissues that express the targeting miRNA. It has also been reported that cisplatin treatment
can increase FAS-mediated apoptosis (186). It is possible that in patients who carry the
variant allele, higher expression of FAS in the presence of cisplatin treatment could increase
tumor cell death resulting in better overall survival independent of treatment regimen, and
this locus might even be synergistic with chemotherapy, thus conferred an more extreme
protective effect. However, further studies will be needed to confirm whether this SNP has
any influence on FAS protein level in vivo and whether it affects apoptotic activity in normal
and tumor cells during treatment. FZD4:rs713065 is the only SNP associated with
significant decreased risk of dying after adjustment for multiple comparisons in surgery-only
patients. This SNP was also the top split in the survival tree analysis of survival for this
subgroup, which suggests its importance in predicting survival for NSCLC patients. FZD4
(frizzled homolog 4) is a member of the frizzled gene family of trans-membrane receptors,
which help to transduce WNT signals and activate downstream WNT-pathway components.
WNT is a major pathway involved in normal and cancer stem cell development (187). This
FZD4 binding site SNP may down-regulate FZD4 expression by creating a miRNA binding
site, thereby inhibiting transduction of the WNT signal. This effect could lead to enhanced
survival in these patients due to decreased WNT signaling. Moreover, this SNP showed an
opposite effect, although not significant, on survival in subgroup treated with surgery plus
chemotherapy, thus indicating the interaction of these variant with chemotherapy on
regulation of Wnt signaling. However, in vitro assessment of the effect of this variant on
miRNA binding was not possible due to difficult sequencing characteristics of this region.
Other appropriate functional assays will be needed to explore the function of this SNP.

67

We further evaluated in a late stage population of all the associations remained
significant in early stage patients. However, none of them were significant at FDR<0.05
level, indicating a stronger effect of these identified SNPs in early stage NSCLCs. One
NAT1 binding site SNP, showed significant effect on survival in all late stage patients and
remained significant after multiple comparison corrections in chemotherapy subgroup.
NAT1 encoded an enzyme catalyzing an acetyl group from acetyl-CoA transfer. This
enzyme assists drug metabolism as well as other xenobiotic and folate catabolism (188, 189).
Thus, it is possible that the real causal SNP would influence chemotherapy compound
metabolism through modulating NAT1 function, and influencing chemotherapy response
and eventually have an impact on patients’ survival, especially in late stage patients, who are
standardly treated with chemotherapy.

In the progression analysis, since majority of late stage patients had metastatic disease at
the time of diagnosis, analysis was only performed in early stage patients. SP1:rs17695156
showed significant association after multiple comparison corrections with increased risk for
disease progression in the overall study population and surgery plus chemotherapy patients.
SP1 is a transcription factor, which can regulate the expression of many genes, thus having a
general, regulatory role within the cell. This SNP is predicted to disrupt a conserved miRNA
site; however, in our in vitro experiments, we did not observe any significant difference
between the two alleles in miRNA-induced repression of reporter activities. Nevertheless, it
is possible that the SNP might show differential effect of miRNA targeting in vivo, where
the expression of various cellular components are at physiological levels. Alternatively, this
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3’UTR SNP might affect SP1 expression independent of its putative role as a miRNA target
site (e.g. affecting RNA stability or post-transcriptional regulation). Any alterations in SP1,
because of its key regulatory role, would potentially have an effect on mechanisms of
disease progression. A variant in DROSHA, a key biosynthesis pathway component, was
associated with significantly increased risk for progression. This result suggests that this
SNP, or variant tagged by it, may alter normal function of DROSHA, thus influencing
overall miRNA processing and affecting different downstream biological processes.

The different patterns of associations with clinical outcomes among the two treatment
subgroups observed in our study suggest that treatment context is important and the
interactions between SNPs and response to treatment may play a major role. In this study,
we identified panels of SNPs exclusively associated with clinical outcomes in either of the
two subgroups with relatively homogeneous treatment regimens. These panels consist of
markers from major pathways related to cancer and provide potential treatment-specific
predictive markers for future investigation. Furthermore, we identified SNPs with different
trends of associations for patients treated with different treatment regimens. This indicates
that miRNA-related regulation of these genes function differently in the context of the
cellular response to chemotherapeutic agents. This suggests that a subgroup of patients may
benefit from chemotherapy, while other patients would not receive this same benefit based
on their genetic background, which may take into consideration in the selection of treatment
regimens.
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Cancer is a multi-factorial disease, meaning that a single gene may not have great
influence on disease risk or clinical outcomes. For the miRNA-related pathway, each
miRNA can regulate a group of genes and miRNA processing genes work together to
produce mature miRNA. Moreover, if these binding site SNPs are present in several
important genes within a cancer-related pathway, we would predict that the cumulative
effect would be much greater than the effect of an individual SNP in isolation. Therefore, it
is reasonable to analyze the potential cumulative effect of these SNPs related to miRNA
function on clinical outcomes. In our study, we observed a strong polygenetic effect and
multiple potential gene-gene interactions for these miRNA-related SNPs. Similar analyses
have been shown in several previous studies to have sufficient power in analyzing patients
for cancer risk and clinical outcomes (190, 191). Interestingly, the most significant SNPs in
the main effect analysis were also those predicted to be involved in potential gene-gene
analyses, demonstrating that these top miRNA-related SNPs identified in our study are not
only important genetic factors individually but they also function in a network to influence
patient’s overall prognosis.

Overall, the current study provides evidence that genetic variants in the miRNA
processing pathway and miRNA binding sites influence clinical outcomes for early stage
NSCLC patients. Specifically, we identified the potential prognostic role of FAS in
predicting overall survival in these patients and supported this observation with in vitro
functional genomic analyses. These findings can help to identify patients who will receive
the most benefit from specific curative therapy regimens, thereby aiming to maximize
treatment efficacy. These results provide a basis for future personalized medicine whereby
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those early stage NSCLC patients with high probability for favorable outcomes can be
identified and appropriately treated.
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3.2

Genetic variations in inflammation related genes and survival in late stage

NSCLC patients

3.2.1

Patient characteristics

A total of 502 patients were included in discovery phase from the MD Anderson
population, all of which were non-Hispanic Caucasians, were included in the discovery
phase (Table 10). At the time of analysis, 68% of the patients had died. The median followup time for the discovery-phase patients was 30.5 months, with a median survival time
(MST) of 16.5 months. The differences in mean age at diagnosis and sex distribution
between patients who had died and those who were alive at the time of analysis were not
significant (Table 10). Half of the patients in the discovery population received radiation
therapy. At the time of analysis, more patients who were current or former smokers than
patients who had never smoked were alive, and more patients with stage III disease than
patients with stage IV disease were alive (P < 0.05; Table 10) . The internal validation
population included 335 patients, with a MFT of 89.6 months and a MST of 16.8 months
(Table 10). Of these patients, 56% had received radiation therapy. At the time of analysis,
more female patients than male patients were alive, and more patients with stage III disease
than patients with stage IV disease were alive (P < 0.05).
In the Harvard population (the external validation set), 371 patients were included, with a
MFT of 60 months and a MST of 12.2 months. The patients who were alive at the time of
analysis were slighter younger at diagnosis than were those who had died (Table 10). One
hundred fifty-three of the 371 patients (41%) had received radiation therapy. The
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distributions of sex, smoking status, and clinical stage were similar between patients who
had died and those who were alive at the time of analysis.
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Table 10: Characteristics of the study populations at the time of analysis
MD Anderson Discovery
Variables
MST (months)
MFT (months)
Age, mean(sd)
Sex
Male
Female
Smoking status
Never
Former
Current & RQ
Clinical stage
Stage III
Stage IV

Dead(%)

Alive(%)

16.5
30.5
60.7(11.2) 62.4(10.5)
166(49)
174(51)

80(49)
82(51)

129(38)
117(34)
94(28)

MD Anderson Validation

P

0.099

Dead(%)

Alive(%)

16.8
89.6
59.3(10.4)
57.5(9.0)

0.907

196(64)
110(36)

12(41)
17(59)

41(25)
74(46)
47(29)

0.012

4(1)
145(47)
157(51)

99(29)
241(71)

72(44)
90(56)

0.001

160(47)
180(53)

92(57)
70(43)

0.041

340

162

Harvard Validation

P

0.374

Dead(%)

Alive(%)

12.2
60.0
63.58(10.55) 60.45(10.76)

P

0.053

0.016

171(54)
147(46)

22(42)
31(58)

0.098

0(0)
13(45)
16(55)

0.782

25(8)
154(48)
139(44)

8(15)
23(43)
22(42)

0.227

142(46)
164(54)

20(69)
9(31)

0.020

118(37)
200(63)

22(42)
31(58)

0.540

165(54)
141(46)

22(76)
7(24)

0.023

128(72)
90(28)

25(47)
28(53)

306

29

318

53

Radiotherapy
Yes
No
Total
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0.344

3.2.2

Effects of inflammation-related SNPs on overall survival

A detailed workflow of our genotyping procedures is presented in Figure 13. A total of
11,930 SNPs from 904 genes were genotyped (see Figure 1), of which 11,689 passed quality
control measures and were included in the MD Anderson discovery phase analysis. We
observed that 1,123 SNPs had significant associations with overall survival in this group (P
< 0.05). Among these, 267 SNPs were found in previously published GWAS chips, for
which data were ready for analysis. Of the remainder, 443 SNPs were associated with linked
SNPs (r2 > 0.8) in previously published GWAS chips; we genotyped the 40 for which the
association was significant (P < 0.2). We also genotyped 413 SNPs that were not found in,
or were not associated with linked SNPs in previously published GWAS chips. After
genotyping (or using existing genotype data) the 657 of these SNPs that passed quality
control measures in the internal validation population, we confirmed the association with
overall survival for 49 SNPs (HRs both >1 or <1, P < 0.05). We then performed a fast-track
external validation of 32 of the 49 internally validated SNPs (those that had existing data
available in previously published GWAS chips in the Harvard population. Seventeen SNPs
were found to have consistent effects on overall survival in all 3 populations (Table 11).
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Figure 13 Study design and workflow.
SNP indicates single nucleotide polymorphism; QC, quality control; MAF, minor allele
frequency; GWAS, genome-wide association study
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Table 11: Inflammation-related single nucleotide polymorphisms (SNPs) that were found to affect overall survival in patients
with late-stage non-small cell lung cancer
MD Anderson
SNP
rs2071554
rs2900420
rs12141256
rs1986649
rs7972757
rs17446614
rs216136
rs2189521
rs1509
rs10964912
rs971768
rs10000856
rs2133092
rs11903566
rs908742
rs3749166

Gene
HLA-DOB
KLRK1
FAF1
FOXO1A
KLRK1
FOXO1A
CSF1R
IL21R
CAPN10
IFNA14
IL17RA
IRF2
TLN2
PRKCE
PRKCZ
CAPN10

Model
DOM
DOM
DOM
DOM
DOM
DOM
ADD
REC
ADD
REC
DOM
ADD
DOM
DOM
DOM
REC

Discovery
HR (95% CI)*
1.46 (1.02-2.09)
0.76 (0.60-0.96)
0.75 (0.57-0.97)
0.76 (0.60-0.96)
0.73 (0.55-0.98)
0.72 (0.56-0.93)
1.21 (1.03-1.42)
1.41 (1.03-1.94)
0.83 (0.69-0.99)
1.49 (1.01-2.19)
1.47 (1.09-1.98)
1.26 (1.07-1.50)
1.30 (1.04-1.63)
1.60 (1.15-2.24)
1.28 (1.03-1.60)
1.41 (1.04-1.92)

P
0.040
0.021
0.031
0.020
0.035
0.011
0.023
0.032
0.038
0.044
0.012
0.007
0.023
0.006
0.024
0.029

Harvard

Validation
HR (95% CI)*
1.51 (1.02-2.25)
0.77 (0.61-0.99)
0.71 (0.52-0.97)
0.75 (0.59-0.95)
0.67 (0.49-0.92)
0.69 (0.53-0.90)
1.17 (1.00-1.37)
1.43 (1.08-1.89)
0.83 (0.68-1.00)
2.00 (1.26-3.17)
1.46 (1.00-2.12)
1.22 (1.03-1.44)
1.30 (1.03-1.64)
1.45 (1.04-2.03)
1.33 (1.06-1.67)
1.42 (1.02-1.99)

Combined
Phet

P
0.041
0.038
0.033
0.018
0.012
0.006
0.046
0.014
0.048
0.003
0.047
0.020
0.027
0.029
0.015
0.038

HR (95% CI)*
1.52 (1.01-2.29)
0.80 (0.63-1.02)
0.87 (0.66-1.13)
0.88 (0.69-1.13)
0.87 (0.66-1.15)
0.89 (0.68-1.16)
1.07 (0.91-1.25)
1.13 (0.85-1.50)
0.93 (0.78-1.11)
1.16 (0.78-1.72)
1.16 (0.78-1.74)
1.06 (0.90-1.25)
1.08 (0.84-1.38)
1.11 (0.74-1.67)
1.03 (0.82-1.29)
1.00 (0.71-1.41)

P
0.045
0.069
0.295
0.322
0.331
0.386
0.410
0.415
0.433
0.462
0.465
0.506
0.543
0.625
0.794
0.992

HR (95% CI)**
1.49 (1.19-1.87)
0.78 (0.68-0.89)
0.78 (0.66-0.91)
0.79 (0.69-0.91)
0.76 (0.64-0.90)
0.76 (0.65-0.88)
1.15 (1.05-1.25)
1.31 (1.10-1.55)
0.86 (0.78-0.96)
1.47 (1.16-1.86)
1.38 (1.13-1.69)
1.18 (1.07-1.29)
1.23 (1.07-1.41)
1.41 (1.15-1.73)
1.21 (1.06-1.37)
1.27 (1.06-1.54)

P
4.32×10-4
3.51×10-4
2.27×10-3
9.43×10-4
1.42×10-3
3.34×10-4
3.46×10-3
1.85×10-3
5.53×10-3
1.38×10-3
1.71×10-3
1.07×10-3
2.88×10-3
1.05×10-3
4.44×10-3
0.012

0.99
0.94
0.60
0.58
0.45
0.36
0.53
0.44
0.57
0.21
0.63
0.29
0.47
0.38
0.23
0.25

* Adjusted for age, sex, smoking status, clinical stage, and treatment regimen.
** Combined (meta-analysis) is based on the fixed-effects model.
Abbreviations: Chr indicates chromosome; HR, hazard ratio; CI, confidence interval; P-het, P for heterogeneity test; DOM, dominant model; REC,
recessive model; and ADD, additive model. Boldface indicates P < 0.1.
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Rs2071554, a missense variation in the first exon of HLA-DOB (major
histocompatibility complex class II, DO beta), was associated with poorer survival in all 3
populations, with similar HRs (Figure 14a). In the discovery population (HR = 1.46, 95% CI
= 1.02- 2.09, P = 0.040), patients carrying at least 1 variant allele (AG or AA) had a
significantly survival disparity of six months from 17 months to 11 months, compared with
those who were homozygous for the common allele (GG), whose median overall survival
time was 17 months (P for log rank test = 0.009; Figure 15a).
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Figure 14 Forest plot for meta-analysis of the association of single nucleotide
polymorphisms
(A) HLA-DOB:rs2071554 and (B) KLRK1:rs2900420, as well as (C) unfavorable genotypes
(UFGs), with overall survival in discovery and internal validation populations
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Figure 15 Kaplan-Meier estimates of HLA-DOB:rs2071554 genotypes and risk of
death in late-stage patients treated with chemotherapy
(A) MD Anderson discovery; (B) MD Anderson validation; (C) Harvard validation. N=A/B,
A: number of patients dead, B: number of all patients. MST: median survival time
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In the internal validation population, rs2071554 was also associated with shortened
overall survival (HR = 1.51, 95% CI = 1.02- 2.25, P = 0.041), and a non-significant, but
appreciable seven month shortened survival time (Figure 15b). A similar effect was
observed in the external validation population. The variant allele was associated with
shortened overall survival (HR = 1.52, 95% CI = 1.01- 2.29, P = 0.045); patients carrying at
least 1 copy of the variant allele had a shorter median overall survival time than patients
who were homozygous for the common allele (P for log-rank test = 0.007; Figure 15c).
Meta-analysis of the association of rs2071554 with overall survival under the fixed
effects model showed a P value of 4.3×10-4 (HR = 1.49, 95% CI = 1.19-1.87, P for
heterogeneity = 0.988 Figure 14a). Rs2071554 is a missense variation that results in an
arginine to glutamine substitution in the first exon of HLA-DOB a gene involved in
phagocytosis and antigen presentation. To determine the potential consequences of this
variant, we used Polyphen2 and SIFT to in silicon evaluate the influence of rs2071554 on
protein structure and function. In Polyphen2 analysis of this missense SNP, the amino acid
change had a Polyphen2 score of 0.923 (sensitivity: 0.80; specificity: 0.94), suggesting that
it may damage protein function; SIFT confirmed this SNP to be deleterious (SIFT score =
0.02).
KLRK1:rs2900420, which is located in the 3’ flanking region of the KLRK1 (killer cell
lectin-like receptor subfamily K, member 1) gene, a component of the natural killer cell
signaling pathway, was associated with prolonged overall survival in the discovery
population (HR = 0.76, 95% CI = 0.60-0.96, P = 0.021) and in the internal validation
population (HR = 0.77, 95% CI = 0.61-0.99, P = 0.038; Figure 14b). Significant overall
survival time advantages were observed for patients who carried at least 1 variant allele
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compared with patients who were homozygous for the common allele (discovery phase: GG,
15 months; AG and AA, 20 months; P for log-rank test = 0.011; internal validation phase:
GG, 15 months; AG and AA, 18 months; P for log-rank test = 0.087). In the Harvard
population, the association of rs2900420 with overall survival reached borderline
significance (HR = 0.80, 95% CI = 0.63-1.02, P = 0.069), and in the meta-analysis, the
effect was highly significant at 3.5×10-4 (HR = 0.78, 95% CI = 0.68-0.89, P for
heterogeneity = 0.945).
Because most of the patients had died at the time of analysis, one year and three year
survival were evaluated for these two validated SNPs in the MD Anderson population;
similar results were found for the 2 SNPs at both durations (data not shown).

3.2.3

Stratified analyses

We next performed stratified analyses for rs2071554 and rs2900420 by smoking status.
Similar effects on overall survival were observed in ever-smokers compared with the overall
population group for each phase for both rs2071554 (discovery: HR = 1.68, 95% CI = 1.052.71, P = 0.092; internal validation: HR = 1.52, 95% CI = 1.02-2.26, P = 0.040; external
validation: HR = 1.47, 95% CI = 0.96-2.25, P = 0.074) and rs2900420 (discovery: HR =
0.68, 95% CI = 0.50-0.93, P = 0.014; internal validation: HR = 0.79, 95% CI = 0.61-1.00, P
= 0.52; external validation: HR = 0.81, 95% CI = 0.63-1.03, P = 0.086). Because of the
limited number of never-smokers, stratified analysis was not performed for this group.
When populations were stratified by stage at diagnosis, the two SNPs showed the same
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effects on overall survival in stage III and stage IV patients as those observed in the overall
population for each population (data not shown).
Because the majority of the patients received platinum-based chemotherapy regimens,
we further did a subgroup analysis of the two SNPs in patients treated with platinum-based
chemotherapy, and yield similar effect as in overall populations (data not shown).

3.2.4

Cumulative effects of the top two SNPs

In the cumulative effects analysis, UFGs were defined as GA or AA for rs2071554 and
GG for rs2900420. Using patients without any UFGs as a reference group within each
population, we observed a significant “gene-dosage” effect of these SNPs on overall
survival: the more UFGs a patient carried, the greater the deleterious effects on overall
survival (discovery: HR = 1.36, 95% CI = 1.11-1.66, P-trend= 0.003; internal validation: HR
= 1.36, 95% CI = 1.10-1.68, P-trend = 0.005; external validation: HR = 1.29, 95% CI =
1.05-1.58, P-trend = 0.015; Figure 14c).
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3.2.5

Discussion

NSCLC patients with advanced stage disease are treated with primary chemotherapy as
standard of care (192). Evidence has demonstrated that inflammation plays a role not only in
lung cancer development, but also clinical outcomes such as response to chemotherapy (2,
193, 194). Thus, it follows that change in patients’ inflammatory responses due to germline
genetic polymorphisms might lead to variations in prognosis. In this analysis, we
systematically evaluated the effect of SNPs from major inflammation-related genes on
overall survival of advanced NSCLC patients who received primary chemotherapy without
resection of their tumor. In our 3-phase pathway-based association study, we found 2
potential prognostic biomarkers for late-stage NSCLC: a HLA-DOB SNP was associated
with poor survival in all 3 populations, and a KLRK1 SNP was associated with prolonged
overall survival in the MD Anderson populations (the association reached borderline
significance in the Harvard population).
HLA-DOB is the beta subunit of the HLA-DO (DO) class II paralogs. It functions as
negative regulator of major histocompatibility complex class II molecules by inhibiting
HLA-DM (DM) molecules in a pH-dependent manner. The DO:DM ratio dictates major
histocompatibility complex class II restricted-antigen presentation efficiency. Evidence has
shown that dysregulation of the antigen presentation pathway related to the inflammatory
response is involved in cancer development (195). Moreover, major histocompatibility
complex class II molecules are key immune response molecules, which have been reported
to have a positive relationship with prognosis in various cancers (196, 197). In our study, we
found that the missense SNP HLA-DOB:rs2071554 may damage protein structure and
function, and we found that it had a robust adverse effect on survival across all 3 populations.
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Hazard ratios indicated that patients with at least 1 variant allele of this SNP had nearly a 50%
increase in risk of death compared with patients carrying no copies of the allele, and KaplanMeier survival analysis showed correspondingly decreased median overall survival times for
carriers of the SNP. Our results suggest a potential prognostic role of this gene in lung
cancer patients, making it worthy of future deep sequencing and functional analysis in vitro.
KLRK1 (member 1 of the killer cell lectin-like receptor subfamily K) encodes for a
transmembrane protein that interacts with various ligands to activate natural killer and T
cells, leading to lysis of tumor cells. This gene has been shown to be involved in
chemoresistance (198). Studies have reported that lung adenocarcinoma cells were able to
escape from the innate immune response of natural killer cells by expressing heterogeneous
ligands for KLRK1 (199). This gene has been identified as a promising target for
immunotherapy for cancer (200, 201). KLRK1:rs2900420 is located 3 kilobases 3’ to the
KLRK1 gene. In our study, it was associated with prolonged overall survival in the MD
Anderson populations and its association with prolonged overall survival was nearly
significant in the Harvard population. It is very likely that with a larger sample size the
results would have reached statistical significance in the external validation population.
Further exploration of the potential underlying biological mechanism(s) of this association
would increase our understanding of this relationship.
This is the largest study to date to investigate the effects of inflammation-related genetic
variations on clinical outcome. The major strength of this study was the 3-phase screening
and validation approach using 2 independent patient populations, which were drawn from
the largest lung cancer clinical outcome studies in the United States. Because the study
populations were both well defined, with extensive clinical data collection, we were able to
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identify a large sample of patients with relatively homogeneous treatment regimens to
identify the most favorable replication population. This is of key importance when
identifying biomarkers predictive of clinical outcome in pathway-based association studies.
Furthermore, instead of limiting our study to top SNPs, an approach usually adopted in
pathway-based association studies to reduce cost and labor, we extensively genotyped
almost all significant SNPs during our internal validation. This strict validation approach
substantially improved the power of our study to detect candidate loci for subsequent
analysis. In addition, we developed a comprehensive panel of inflammation-related genetic
variations, which covered major cellular processes involved in inflammation responses and
regulations. With this extensive coverage, our results provided a broad overview of the role
of genetic variation in these essential genes within the overall inflammation network in
modulating patients’ clinical outcomes.
In conclusion, we identified and validated 2 potential genetic markers within the
inflammation pathway that may affect clinical outcome in patients with late-stage NSCLC
treated with chemotherapy. Given the important role of inflammation throughout the cancer
continuum, these genetic markers may be good potential prognostic markers to help in
tailoring treatment regimens in the clinic.

86

3.3

Genetic variations in inflammation pathway and survival in NSCLC patients in

never smokers

3.3.1

Patient characteristics

In the MD Anderson study, we identified 411 never-smokers with NSCLC (Table 12).
Sixty-seven percent of them were women, and adenocarcinoma was the most common
histology (77%). The mean age at diagnosis was 61.5 years. The median survival time (MST)
was 23.2 months, and the median follow-up time (MFT) was 54.2 months. Most of the cases
(77%) were diagnosed at a late stage (stage III/ IV). Fifty-three percent of the patients
received chemotherapy only, 33% underwent surgery, and 24% received radiation-therapy.
At the time of the current study, 276 (67%) of the patients had died. In the Mayo Clinic
study, 311 never-smokers with NSCLC were identified and included as the validation
population (Table 12). The mean age was 61.7 years, with the majority being female (73%).
Sixty-one percent of the patients had late-stage disease at diagnosis. Fifty-nine percent of the
patients received chemotherapy, 53% underwent surgery, and 25% received radiationtherapy. At the time of this study, 59% of the patients had died. Because of the greater
proportions of patients with early-stage disease and who had undergone surgery in the Mayo
Clinic population than in the MD Anderson population, the MST (44.6 months) and MFT
(73.6 months) were longer in the former population than in the latter.
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Table 12: Characteristics of the never-smokers with lung cancer

Characteristic

MD Anderson

Mayo Clinic

No. of patients (%)

No. of patients (%)

MST, months

23.2

44.6

MFT, months

54.2

73.6

61.5(13.0)

61.7(13.1)

Male

135(33)

84(27)

Female

276(67)

227(73)

I

93(23)

105(34)

II

15(4)

15(5)

III

91(22)

90(29)

IV

212(52)

101(32)

316(77)

213(68)

Squamous cell carcinoma

28(7)

14(5)

Non-small cell carcinoma

41(10)

18(6)

Bronchoalveolar carcinoma

20(5)

11(4)

Other

6(1)

55(18)

Surgery

135(33)

165(53)

Radiation therapy

100(24)

77(25)

Chemotherapy

218(53)

182(59)

38(9)

36(12)

Dead

276(67)

182(59)

Alive

135(33)

129(41)

411

311

Mean age, years (SD)
Sex

Stage

Histology
Adenocarcinoma

Treatment

Concurrent chemoradiation
Vital status

Total
SD=standard deviation.

88

3.3.2

Main effect of individual SNP on survival in the discovery, replication, and

combined analysis
In the discovery phase, after carrying out quality control measures, 11,689 SNPs were
included in our analysis. Of these SNPs, 1,538 were significantly associated with overall
survival (p<0.05), with 14 of these variants being significant at the p<10-4 level.
We selected 37 top SNPs for validation in the Mayo Clinic population. Eighteen SNPs
had a consistent direction of the effect (HR same direction) in both populations (table 13).
Of these 18, three SNPs ((interleukin 17 receptor A [IL17RA]:rs879576, bone
morphogenetic protein 8A [BMP8A]:rs698141, and spleen tyrosine kinase [SYK]:rs290229)
in the Mayo population were significant (p<0.05) with an additional two (CD74:rs1056400
and CD38:rs10805347) reaching borderline significance (p<0.1)
The most significant SNP was rs879576, a synonymous variant in the last exon of the
proinflammatory cytokine IL17RA. Rs879576 was associated with a significantly decreased
risk of death in the discovery phase (hazard ratio [HR], 0.57; 95% confidence interval [CI],
0.41-0.78; p=5.49 × 10-4), validation phase (HR, 0.65; 95% CI, 0.44-0.94; p=0.023) and
combined population (HR, 0.60; 95% CI, 0.47-0.77; p=4.13 × 10-5) (Table 13). This
decreased risk of dying resulted in enhanced survival duration. Compared to patients with
variant genotypes, a prolonged MST was observed in patients with the common
homozygous genotype in both discovery (31 vs. 20 months, p=0.066, log-rank test) and
validation (46 vs. 34 months, p=0.069, log-rank test) phases. (Figures 16a and 16b)
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Table 13: SNPs with the same trend in both the MD Anderson and Mayo Clinic populations
MD Anderson(discovery)
Position
Chr22:15969246
Chr9:92674234

Gene
IL17RA
SYK

SNP
rs879576
rs290229

Model
DOM
DOM

HR (95% CI)*
0.57 (0.41-0.78)
1.58 (1.23-2.03)

Mayo Clinic (validation)

p

HR (95% CI)*

p

Combined analysis**
HR (95% CI)**

p

p-het

5.49 × 10

-4

3.03 × 10

-4
-4

1.73 (1.03-2.91)

0.038

1.84 (1.37-2.46)

4.29 × 10

1.24 (0.86-1.79)

0.240

1.56 (1.25-1.95)

7.43 × 10-5

0.123

-4

0.403

0.65 (0.44-0.94)
1.43 (1.01-2.02)

0.023
0.046

0.60 (0.47-0.77)
1.53 (1.25-1.87)

4.13 × 10

-5

0.610

4.15 × 10

-5

0.635

-5

0.789

Chr1:39738348

BMP8A

rs698141

DOM

1.89 (1.33-2.68)

4.04 × 10

Chr9:21397604

IFNA8

rs4978115

REC

1.79 (1.35-2.36)

4.39 × 10-5
-4

0.71 (0.48-1.04)

0.080

0.62 (0.49-0.79)

1.00 × 10

1.23 (0.75-2.04)

0.412

1.65 (1.28-2.13)

1.36 × 10-4

0.188

-4

0.616

Chr5:149800000

CD74

rs1056400

DOM

0.58 (0.43-0.78)

3.54 × 10

Chr9:21403703

IFNA8

rs13296822

REC

1.83 (1.36-2.47)

7.76 × 10-5
-4

0.55 (0.28-1.07)

0.080

0.48 (0.33-0.70)

1.75 × 10

1.59 (0.87-2.92)

0.134

2.16 (1.44-3.25)

1.90 × 10-4

0.184

-4

0.474

Chr4:15449937

CD38

rs10805347

REC

0.45 (0.28-0.72)

7.93 × 10

Chr20:36392996

BPI

rs5743539

DOM

2.77 (1.61-4.77)

2.45 × 10-4
-4

0.80 (0.60-1.07)

0.133

0.74 (0.63-0.87)

2.10 × 10

0.82 (0.60-1.12)

0.219

0.72 (0.59-0.87)

6.78 × 10-4

0.290

-4

0.168

Chr13:101700000

FGF14

rs1336726

ADD

0.71 (0.58-0.86)

5.34 × 10

Chr16:86446704

SLC7A5

rs4240803

DOM

0.66 (0.52-0.84)

8.39 × 10-4
-4

1.17 (0.80-1.73)

0.417

1.47 (1.17-1.83)

7.17 × 10

0.87 (0.58-1.30)

0.488

0.67 (0.53-0.86)

1.18 × 10-3

0.141

-3

0.178

Chr9:92684769

SYK

rs1755938

DOM

1.63 (1.25-2.14)

3.68 × 10

Chr7:2744970

GNA12

rs11971014

DOM

0.59 (0.44-0.80)

4.77 × 10-4
-4

0.86 (0.63-1.18)

0.363

0.73 (0.60-0.88)

1.19 × 10

1.13 (0.74-1.75)

0.568

1.57 (1.20-2.07)

1.20 × 10-3

0.056

-3

0.082

Chr21:33599261

IL10RB

rs2834178

DOM

0.66 (0.51-0.84)

6.96 × 10

Chr6:152500000

ESR1

rs9341066

DOM

1.96 (1.37-2.79)

2.01 × 10-4
-4

0.92 (0.65-1.31)

0.660

0.72 (0.59-0.88)

1.43 × 10

1.10 (0.76-1.57)

0.618

1.42 (1.14-1.78)

1.92 × 10-3

0.070

-3

0.421

Chr9:92665566

SYK

rs1572104

DOM

0.63 (0.49-0.81)

3.12 × 10

Chr12:6766579

LAG3

rs11064386

DOM

1.68 (1.26-2.23)

3.74 × 10-4
-3

Chr5:172100000

DUSP1

rs4868204

DOM

0.69 (0.53-0.91)

9.40 × 10

Chr7:41713523

INHBA

rs12532252

REC

1.34 (1.00-1.79)

0.050

0.84 (0.58-1.23)

0.373

0.74 (0.59-0.93)

8.67 × 10

1.17 (0.79-1.72)

0.442

1.27 (1.01-1.61)

0.042

0.580

*Adjusted according to age, sex, clinical stage, and treatment regimen.**Combined (Meta) analysis based on fixed effects model. Boldface: p<0·1.
p-het=P for heterogeneity test; DOM=dominant model; REC=recessive model; ADD=additive model.
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Figure 16 Kaplan-Meier estimates of the effect of selected SNPs on survival probability
in never-smokers with lung cancer
(A)IL17RA:rs879576 in the MD Anderson population(discovery phase). (B)
IL17RA:rs879576 in the Mayo Clinic population(validation phase).(C) SYK:rs290229 in the
MD Anderson population (discovery phase). (D) SYK:rs290229 in the Mayo Clinic
population(validation phase).(E)BMP8A:rs698141 in the MD Anderson population
(discovery phase). (F) BMP8A:rs698141 in the Mayo Clinic (validation
phase).(G)CD74:rs1056400in the MD Anderson population (discovery phase). (H)
CD74:rs1056400 in the Mayo Clinic population (validation phase). (I)CD38:rs10805347 in
the MD Anderson population (discovery phase). (J) CD38:rs10805347 in the Mayo Clinic
population (validation phase); MST: median survival time in months. N=A/B, A: number of
patients with event, B: total number of patients.
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Rs290229 is an intronic SNP in SYK, a gene that encodes for a non-receptor type Tyr
protein kinase. This SNP was associated with a significantly increased risk of death in both
the MD Anderson (HR, 1.58; 95% CI, 1.23-2.03; p=3.03 × 10-4), Mayo Clinic (HR, 1.43; 95%
CI, 1.01-2.02; p=0.046), and combined (HR, 1.53; 95% CI, 1.25-1.87;p=4.15 × 10-5)
populations. Although not significant, both study populations had the same trend of
decreased MST (Figures 16c and 16d).
Rs698141 is located in intron of BMP8A, a gene involved in cytokine signaling
transduction. Patients who had at least one variant allele had a nearly two-fold increase in
risk of death in both the MD Anderson (HR, 1.89; 95% CI, 1.33-2.68; p=4.04 × 10-4) and
Mayo Clinic (HR, 1.73; 95% CI, 1.03-2.91; p=0.038) and combined (HR, 1.84; 95% CI,
1.37-2.46; p=4·29 × 10-5) populations (Table 13). The MST was 23 months in patients with
the common homozygous genotype and 16 months in patients with the heterozygous or
homozygous variant genotypes in the MD Anderson population (p=9.1 × 10-4, log-rank test)
(figure 1e). We also observed a similar longer MST (24 months) in the Mayo population
(p=0.044, log-rank test) (Figure 16f).
CD74:rs1056400 (3’-untranslated region) and CD38:rs10805347 (intronic) were
significantly associated with an increased risk of death in the MD Anderson population but
were borderline significant in the Mayo Clinic population (Table 13). Although not
statistically significant, the trend of differing survival times by genotype was observed
(Figures 16g and 16h).
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3.3.3

Main effects of individual SNPs on survival stratified by histology and stage

Because the majority of never-smokers with lung cancer have adenocarcinoma, we
performed a subgroup analysis of survival in patients with adenocarcinoma. The results were
similar to those of the overall analysis of all study patients (Table 14). We further performed
a stratified analysis of the five top SNPs according to disease stage. Specifically, we
combined the MD Anderson and Mayo Clinic patients and stratified them according to
early-stage (I and II) and late-stage (III and IV) lung cancer. The results showed that all five
SNPs were significantly associated with survival in the late-stage patients, an association
that was comparable with or even stronger than that in the overall population. Because of the
limited sample size and number of deaths in the early-stage patients, this association was not
as robust. However, the same trend of effect for all five SNPs was observed in the earlystage patients (data not shown).
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Table 14: Effect of selected SNPs on survival in adenocarcinoma patients
MD Anderson (discovery)
Gene

SNP

Model HR (95% CI)*

p

CD74

rs1056400

DOM

0.60 (0.42-0.85) 3.95 × 10-3

CD38

rs10805347

REC

BMP8A

rs698141

SYK
IL17RA

Mayo Clinic (validation)
HR (95% CI)*

Combined analysis**

p

HR (95% CI)**

p

p-het

0.57 (0.36-0.91)

0.017

0.59 (0.44-0.78) 1.86 × 10-4 0.902

0.27 (0.14-0.52) 9.77 × 10-5

0.64 (0.30-1.33)

0.228

0.40 (0.24-0.65) 2.01 × 10-4 0.093

DOM

2.04 (1.38-3.04) 4.09 × 10-4

1.52 (0.80-2.87)

0.199

1.88 (1.34-2.64) 2.34 × 10-4 0.438

rs290229

DOM

1.58 (1.18-2.11) 2.20 × 10-3

1.43 (0.97-2.12)

0.073

1.52 (1.21-1.93) 4.22 × 10-4 0.696

rs879576

DOM

0.57 (0.40-0.83) 3.31 × 10-3

0.65 (0.42-1.00)

0.050

0.61 (0.46-0.80) 4.57 × 10-4 0.660

*Adjusted according to age, sex, clinical stage, and treatment regimen. ** Combined (Meta) analysis based on fixed effects model. Boldface:
p<0·1. p-het=P for heterogeneity test; DOM=dominant model; REC=recessive model.
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3.3.4

Main effects of individual SNPs on survival in ever-smokers

We next analyzed overall survival in the 996 ever-smokers at MD Anderson to assess the
effects of the five SNPs described above on survival according to smoking status. The eversmokers were slightly older than the never-smokers (mean age, 64.8 years vs 61.5 years) and
had a smaller proportion of women (42% vs 67%) and adenocarcinoma cases (52% vs 77%).
The treatment regimens in the two groups were similar. None of the SNPs validated in the
never-smokers were significantly associated with survival in the ever-smokers (Table 15).
We further stratified the ever–smoker patients into former and current smokers and did not
observe any significant associations within these subgroups (data not shown).
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Table 15: Effect of selected SNPs on survival according to smoking status in the MD
Anderson population
Never-smokers
Gene

SNP

Model

SYK

rs290229

DOM

1.58 (1.23-2.03) 3.03 × 10-4

1.12 (0.94-1.33) 0.214

CD74

rs1056400

DOM

0.58 (0.43-0.78) 3.54 × 10-4

0.93 (0.75-1.15) 0.487

BMP8A

rs698141

DOM

1.89 (1.33-2.68) 4.04 × 10-4

1.06 (0.81-1.40) 0.655

IL17RA

rs879576

DOM

0.57 (0.41-0.78) 5.49 × 10-4

0.89 (0.72-1.10) 0.266

rs10805347

REC

0.45 (0.28-0.72) 7.93 × 10-4

0.91 (0.67-1.24) 0.557

CD38

HR (95% CI)*

Ever-smokers
p

HR (95% CI)*

*Adjusted according to age, sex, clinical stage, and treatment regimen. Boldface: p<0·1.
DOM=dominant model; REC=recessive model.
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p

3.3.5

Survival tree analysis

Survival tree analysis was used to identify higher order gene-gene interactions among
these five SNPs in modulating risk of death. Using the MD Anderson never-smoker
population as a training set, we identified two SNPs (CD74:rs1056400 and
BMP8A:rs698141) potentially having gene-gene interactions. Patients with the
rs1056400_GG/rs698141_GA+AA genotype (node 3) had a 2.32-fold greater risk of death
(HR, 2.32; 95% CI, 1.58-3.41; p=1.72 × 10-5) and significantly shorter MST (14 months vs
23 months; p=4.5 × 10-4, log-rank test) than did patients with the
rs1056400_GG/rs698141_GG or rs1056400_GA+AA genotype (nodes 1 and 2). This tree
model was validated in the Mayo Clinic population: patients with the
rs1056400_GG/rs698141_GA+AA genotype (node 3) had a nearly twofold greater risk of
death (HR, 1.97; 95% CI, 1.11-3.50; p=0.02) and a strikingly shorter MST (by 26 months)
than did patients with the rs1056400_GG/rs698141_GG or rs1056400_GA+AA genotype
(nodes 1 and 2) (p=0.029, log-rank test) (Figure 17).
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Figure 17 Potential gene-gene interactions among SNPs validated in the survival tree
analysis
(A) Survival tree analysis results and Kaplan-Meier estimates in the MD Anderson
population (discovery phase). (B) Survival tree analysis results and Kaplan-Meier estimates
in the Mayo Clinic population (validation phase). MST: median survival time in months.
N=A/B, A: number of patients with event, B: total number of patients.
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3.3.6

Discussion

NSCLC in never-smokers is unique from that in ever-smokers due to distinct clinical,
histological, and genetic characteristics. These attributes warrant specific investigation of
never-smokers. Although we are in the era of the genome-wide association study (GWAS),
the coverage of certain genetic region on commercial available GWAS chips is not sufficient
for detailed genetic analysis; this limits the power of GWAS to identify all genetic
determinants. Thus study design based on prior knowledge focusing on known cancer
relations is indispensable. In this context, we conducted a two-stage, discovery-validation
study to identify genetic predictors of overall survival in never-smokers with lung cancer
using a pathway-based approach. By systematically evaluating SNPs in major inflammatory
pathways, we found five SNPs in CD74, CD38, SYK, BMP8A, and IL17RA that were
significantly associated with overall survival in these patients. Furthermore, we analyzed
and validated a survival tree model in predicting survival that takes gene-gene interactions
into consideration. In comparing the associations of SNPs with survival in ever- and neversmokers, we provided evidence of distinct roles for inflammatory genetic determinants of
prognosis in never-smokers with lung cancer.
Two SNPs—IL17RA:rs879576 and BMP8A:rs698141—are related to cytokine signaling.
IL17RA is an isoform of the interleukin (IL)-17 receptors. In the presence of IL-17 ligands,
these receptors can activate various downstream signaling pathways to induce macrophage
recruitment, angiogenesis, and inflammatory lung diseases.(202, 203) In our study,
IL17RA:rs879576 was associated with a consistent protective effect against death and
corresponding prolonged MSTs in both the MD Anderson and Mayo Clinic populations.
This is a synonymous SNP located in the last exon of IL17RA that may influence the
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structure and/or regulation of its host gene. BMP8A is a member of the transforming growth
factor β superfamily (204). BMP proteins play important roles in cell differentiation,
proliferation, survival, and apoptosis and are implicated in tumor cell migration, metastasis,
and angiogenesis in various cancers (205-208). Rs698141 is located in the first intron of
BMP8A, and not in any obvious functional elements. Therefore, it is most likely linked with
other functional SNPs that result in BMP8A altered function. Authors have reported that
tobacco smoking can lead to immunosuppression and downregulation of proinflammatory
cytokines specifically in the lung tissues, suggesting important roles for cytokines in lung
pathology.(209) Cytokine signaling pathway variants were predominant in our validated
SNPs highlighted the potential roles of cytokines in determining prognosis for lung cancer in
never-smokers.
SYK belongs to the Syk family of tyrosine kinases and plays an oncogenic role in
different cancers.(210) In lung cancer cells, SYK is silenced owing to hypermethylation in its
promoter region.(211) SYK:rs290229 was associated with an increased risk of death and
reduced survival in our populations. This SNP is located in an intron; it is possible that this
SNP tagged another causal variant that affects the function of SYK. Further deep sequencing
would be warranted to identify the potential casual locus responsible for this finding.
Two other SNPs—CD38:rs10805347 and CD74:rs1056400—were borderline significant
in our validation. CD74 is a member of a class of polypeptides involved in antigen
presentation that is a potential therapeutic target and prognostic factor for cancer (212-215)
with involvement in lung adenocarcinoma. Our results suggested the potential prognostic
role of CD74:rs1056400 regarding overall survival in lung cancer patients. CD38 is a
multifunctional single-chain type II transmembrane glycoprotein, related to the development
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of viral infections, diabetes, and cancer.(216) Studies have shown a prognostic role for
CD38 in leukemia patients.(217) We observed a consistent protective effect for
CD38:rs10805347 against death, which indicated a potential role for this gene in solid
cancers in addition to leukemia.
In the current study, we aimed at identify specific prognostic markers for never smokers.
Although incidence is increasing, lung cancer in never smokers represents only ~10% of all
lung cancer cases. Thus, to identify a homogeneous never smoking patient cohort with
adequate demographic/clinical variables is a challenge. In this study, we were able to
identify relatively large and well-characterized study populations from two study sites with
complete collection of clinical and epidemiological data that enabled us to recruit a
sufficient study population. This provided an important resource contributing to the
understanding of this disease which has emerged as a major public health problem tracking
smoking and smoking cessation rate. Interestingly, none of the five SNPs were significantly
associated with overall survival in ever-smokers, providing additional evidence of lung
cancer in never smoker as a distinct disease and requires identifying specific prognostic
markers.
Moreover, the multi-stage study design with two independent patient populations largely
reduced the likelihood of false-positive results for the SNPs that were significant in both
populations. Therefore, although a portion of the findings would not be judged significant
due to multiple comparisons, the replication provides a mechanism to address these concerns,
attenuating the need for strict multiple comparisons correction. Another significant finding
in our study was the identification and validation of a survival tree, which has proven to be a
powerful analytical tool regarding survival in cancer patients based on higher order gene-
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gene interactions (37-39). The survival tree analysis stratified the Mayo Clinic patients into
significantly different risk subgroups in a manner similar to that in the MD Anderson
patients. Beyond the effect of a single SNP on survival, the survival tree takes into account
the complicated interactions of genes which are yet not discovered and has high predictive
power regarding patients’ prognosis that may be clinically applicable.
In conclusion, this is the first large-scale study to examine the association of SNPs in 800
inflammation-related genes with survival in never-smokers with lung cancer. The identified
individual SNPs and the survival tree may be applicable to future modeling of clinical
outcome for prediction of survival following validation in other independent populations of
never-smokers with lung cancer.
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Chapter 4: Conclusions
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Overall, the current study provides evidence that genetic variants in the miRNA and
inflammation related pathways could influence clinical outcomes for NSCLC patients.
We evaluated miRNA pathway SNPs for their potential prognostic role and have
identified some significant findings. Specifically, we identified a FAS gene binding site SNP
that may predict overall survival in these patients and supported this observation with in
vitro functional genomic analyses. We also identified and validated potential genetic
markers within the inflammation pathway that may affect clinical outcome in NSCLC
patients, particularly in never smokers and late-stage patients. Moreover, we have identified
and validated a survival tree which has proven to be a powerful analytical tool regarding
survival in never smoker cancer patients based on higher order gene-gene interactions.
Given the important role of miRNA and inflammation throughout the cancer continuum,
these genetic markers may be good potential prognostic markers that can help tailor
treatment regimens in the clinic.
With further functional analysis and validations, these findings can help increase the
prediction accuracy for traditional prognostic factors in predicting patients’ prognosis
through identification of optimal treatment and follow-up care regimens.
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Chapter 5: Strength and Limitations
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One of the greatest strengths of our studies is the relatively large sample size.
Studying never smoking lung cancer patients, a population that accounts for only ~10% of
all lung cancer cases, can be difficult because identifying a homogeneous never smoking
patient cohort with adequate demographic/clinical variables is usually a challenge. In the
current study, we were able to identify relatively large and well-characterized study
populations from two study sites with complete collection of clinical and epidemiological
data that enabled us to recruit a sufficient study population. Tracking smoking and smoking
cessation rates in large populations of lung cancer patients like this one can play a major role
in understanding the disease. The detailed clinical information collected for these study
subjects has enabled us to further investigate association in specific subgroups and helped us
identify several treatment specific markers that may help to evaluate potential risks and/or
benefits of different treatment regimens for patient subgroups with specific genotypes.
Further studies of these SNPs in an independent population would be valuable in confirming
our results. Moreover, the comprehensive query of SNPs from genes involved in both
miRNA regulating and inflammatory responses provide a broad overview and investigation
of the role of these genetic variations in modulating patients’ clinical outcomes.

False discovery is an inherited issue for large scale association studies. We are aware
that there is a chance of false discovery in our results. To correct for this beyond controlling
for false discovery with a statistical strategy (FDR), we adopted several other approaches to
further validate and study our findings. Since inflammation related SNPs are tagging SNPs,
commonly as intronic polymorphisms, we adopted a multi-stage study design with
independent patient populations identified from three of the largest lung cancer studies in the
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US (MD Anderson, Mayo Clinic, and Harvard University) to which largely reduced the
likelihood of false-positive results for the SNPs that were significant in all populations.
Therefore, although a portion of the findings would not be judged significant due to multiple
comparisons, the replication provides a mechanism to address these concerns attenuating the
need for strict multiple comparisons correction. Furthermore, instead of limiting our study to
top SNPs, an approach usually adopted in pathway-based association studies to reduce cost
and labor, we extensively genotyped almost all significant SNPs during our internal
validation. This strict validation approach substantially improved the power of our study to
detect candidate loci for subsequent analysis. For those potentially functional (miRNA
binding sites, non-synonymous) SNPs, either in vitro (luciferase reporter assay) or in silicon
(SIFT/Polyphen), functional analysis was performed to evaluate influence of these variants
to gene or protein function to help better understanding our results.
An additional limitation of our study is due to the location of our SNPs. Most of our
validated SNPs are located in intron- or intra-genic regions so their function to host or
nearby genes are not clear. As a result, further fine-mapping or deep sequencing would be
needed to discover the causal allele. In addition, although we performed functional analysis
for miRNA binding sties polymorphisms, assays have not been performed in protein level or
in vivo. Following-up deeper analysis for their functions is warranted.
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Chapter 6: Future Directions
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In the current studies, we only focused on two critical pathways. There are other
pathways also important for the understanding of lung cancer clinical outcomes. Thus, we
will continue to identify and analyze more interesting pathways to gain a better overview of
genetic variations contributing to patients’ clinical outcomes.
We will make effort to seek collaborations and identify other independent
populations with adequate and comparable repository of clinical and epidemiological data,
to provide additional statistical power, and further validate our results. At the meantime,
with the continuous recruitment of cases and longer follow-up time in our study and other
ongoing GWAS of lung cancer in the field, we will have sufficient power to conduct GWAS
of clinical outcomes.
After validated our findings, functional characterization and phenotypic analysis will
be the major focus for our future studies. Deep sequencing or fine-mapping will be used to
identify real causal allele tagged by intronic SNPs found in our study. Then, functional
analysis will be designed accordingly. Luciferase assays will be designed and performed
where feasible. For those SNPs that have already undergone functional analysis, further and
deeper biological characterization will be done to test for their functions at the gene and
protein level. When sample available, phenotypic assay, such as gene expression or protein
array, will be designed to further explore the prognostic values of the identified genes. Mice
models can be developed in collaboration with other basic science laboratories if feasible.
With more solid and comprehensive results as well as deeper understanding of the
influence of the genetic variations on NSCLC clinical outcomes, these identified markers
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could be incorporated into a prognosis prediction model to increase prediction accuracy in
both population and individual level.
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